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ASST
in this study, I have attempted to develop an
optimal and' effective process. for the production of
monoclonal antibodies to human liver alcohol
dehydrogenase. In order to increase the number of
hybrids obtained per fusion and to improve
reproducibility, a selective combination of various
technical parameters was used. These include different
immunization regimens, removal of erythrocytes, use of
feeders, different ratios of spleen to myeloma cells,
different types of. polyethylene glycol (PEG), and
different methods for selecting the desired hybrids.
Atypical- human alcohol dehydrogenase (ADH) was
used as the antigen. Being a dimeric isoenzymes, ADH
from Chinese 1 iver consists mainly of a2, 22 and 2Y1.
Each subunit contributes to different degree of enzyme
activity. Aiming to study the subunit interaction and
the physiological significance of individual
polymorphism, four monoclonal antibodies to ADH• have
been produced, three of them are IgM and one of them is
IgG 1, Each of these antibodies has been found to bind
the enzyme with high affinity. In addition, they also
exhibit proportional inhibition pattern on enzyme
activity.
1CHAPTER 1 GENERAL INTRODUCTION
1. 1 Introduction
At the end of nineteenth century, many
scientists have begun to utilize antibodies widely in
their research work. The unique properties of
antibodies in recognizing the shape- of particular
determinants on the surface of antigen and binding
tightly to them allow antibodies to become a powerful
tool in detecting, isolating and analysing biological
materials. Actually, antibodies isolated from serum of
immunized animals. are derived from hundreds or thousands
of different antibody-secreting clones. Many of these
products may be directed against undesired antigens,
such as impurities in the immunising antigen, or
molecules which are closely related to it. In addition
to these undesirable specificities towards a wide range
of determinants, the specificities and titer of one
batch-of antibodies vary widely from one to another.
In 1975, Kohler and Milstein demonstrated that
individual clones of normal antibody-secreting cells
could be immortalised by fusing with -myeloma cells. The
resulting 'hybridoma' approach has moved serology into
a new era of precision. In one blow, the major
problems of specificity and reproducibility were solved.
Virtually, unlimited quantities of homogenous,
exquisitely specific antibodies could be produced, even
2if the immunising antigen was not pure.
The power of this new technique was quickly
appreciated, and immunology journals were soon flooded
with reports of monoclonal antibodies to a wide range of
biochemical substances, such as enzymes, membrane
receptors, bacterial/viral membrane markers, hormones,
drugs, polysaccharides, etc.. This is not surprising as
hybridoma technology explores deeper area where
serological approach has not been considered feasible.
This important breakthrough led the inventors earn the
Nobel Prize in 1984.
Monoclonal antibodies have now been applied for
a variety of studies. Examples of these include probes
for the fine structure of proteins, radioimmunoassay of
hormones and drugs, histocompatibility testing, tumour
localisation and classification, immunotherapy,
purification of molecules by affinity chromatography,
microbial and parasitic disease, neurochemistry and
embryology. Moreover, monoclonal antibodies have also
proven invaluable as a `probe' for previously
unidentified molecules, such as new antigens on the
surface of subpopu l at ions of lymphocytes.
1.2 History of production of monoclonal antibodies
It is a historical curiosity that a monoclonal
antibody producing cell line against known antigen mad
3have been generated by cell fusion as early as 1969.
Sinkovics et al in 1966 reported that after injecting a
diploid virus-producing lymphoma into the peritoneal
cavity of a mouse, they recovered a tetraploid cell line
which in vitro produced two types of immunoglobulins and
factors having virus-neutralizing activity. The
experiment was never successfully repeated, nor was it
conclusive that cell fusion had occurred (Sinkovics et
al.., 1969). Later, others: suggest that the
immunoglobulins were the neutralizing factors and that
the cell line arose by an in vivo fusion of a lymphoma
cell 'to an antivirus-producing lymphocyte (Yelton et
al., 1981).
Methods for promoting cell fusion were first
reported during the 1960s by Professor Henry Harris and
colleagues at the University of Oxford (Harris et al.,
1965). They used inactivated Sendai virus as their
fusion agent. This caused widespread interest in cell
fusiori techniques and several hybrids carrying nuclei
from widely differing animal species were produced, but
only a few of them are stable, persisting permanently as
cultured cell lines. Thus, the fusion technique was
successfully established, but its usefulness was not
widely appreciated until only after Kohler and Milstein
utilized it in hybridoma technology.
At that time, Milstein's group at the Medical
4Research Council Laboratory of Molecular Biology in
Cambridge was studying how somatic cells diversify in
culture and how mutations modify the combining
specificity of antibodies. By 1973, Mi lstein' s group
and Scharff's group, respectively, produced structural
mutants of a mouse myeloma protein secreted by a
cultured cell line. However, the search for these
mutant proteins was laborious because the proteins made
by the parental cells lacked. recognizable antibody
activity, changes in which would be the most effective
indication of slight differences caused by mutations.
Clearly what was needed was a cell line that secreted an
immunoglobulin exhibiting antibody activity that could
be easily assayed. No such lines existed and this idea
was not pursued further until-only when Kohler joined
his laboratory.
Meanwhile, Milstein and Cotton in 1973 follower
another line of research and did an experiment to
the transcription of DNA.
As the synthesis of antibodies is controlled by
two sets of genes. One set encodes the variable
region of the antibody molecule's light and heavy
chains, the region that controls antibody specificity
the other set encodes the constant region of the
chains, the region that is responsible for its effector
demonstrate that no allelic exclusion occurred during
5functions. Each lymphocyte synthesizes an antibody
encoded by a single pair of V (for variable) and C (for
constant) genes out of a large repertory of such genes
in the cell, and when there are different alleles, or
variant forms of a V or a C gene on each of the cell's
two chromosomes, what would be the molecular combination
of the V and C genes? To answer this, Milstein's group
fused two myeloma cells, one from a mouse line and one
from a rat line. Analysis of the hybrid cells showed
that they secreted hybrid molecules consisting of
various combinations of the chains synthesized by the
parental cells but never a combination of a V region
from one animal and a C region from the other. This led
to the conclusion that the genes for the V and C regions
must be on the same chromosome. (Now we know that the
DNA sequences coding for the V and the C regions are
separated by introns, and the entire stretch of DNA is
transcribed into a complementary strand of RNA, which is
then processed by-restriction enzymes. The sequences
coding for the V and the C regions are then spliced
together to make the mRNA which are finally translated
into the polypeptide chain of immunoglobulin chain.)
The historial moment came when Georges Kohler
went to Milstein's laboratory as a postdoctoral fellow
in 1974. They used mutant rnyeloma as a tool to learn
more about the 'genetic control of the synthesis of
antibodies. The lack of a myeloma cell line having
6specific measurable activity was still a large hindrance
to their progress. Yet the experiments done by Cotton
and Milstein gave a hint to Kohler, as the information
from both parents of the fused cells was Is codominantly
expressed by the hybrids, there was no allelic
exclusion. So it would be possible to immortalize an
antibody-producing plasma cell by fusing it with a
myeloma cell, a mutant cell line with measurable
activity will thus be produced.
In their experiment, they chose sheep red blood
cells as the immunogen. Spleen cells from immunized
mice were fused-with mouse myeloma cells employing
Sendai virus. Fused cells-were identified in a selective
medium and were found to secrete immunoglobulins from
both parents. The one secreted antibody against the rod
blood cells was isolated and maintained in culture.
After the initial success, Milstein and Kohler ran into
trouble and no progress was made in all their
experiments. Giovanni Galfre then came and tried out
various modifications of the fusion technique, in
particular. the use of polyethylene glycol. Eventually
the basic problem was discovered: one of the reagents
was found to be toxic.
Once this fault was corrected, with the
cooperation of Jonathan C. Howard and Geoffrey W.
Butcher, Milstein's group was able to establish a
7standard protocol and develop many- hybrid antibody-
producing cell lines of interest
1.3 Improved strategies of Hybridoma Technology
Ten years after the discovery of the' Hybridoma'
technology, a number of technical parameters has been
reported in an attmept to increase the number of hybrids
obtained per fusion and to improve reproducibility.
These include different immunization regimens, various
myeloma partners and different ratios of spleen to
myeloma cells, different types of polyethylene glycol
(PEG),. conditions of treatment with PEG, and different
methods of selecting the desired hybrids. Many
combinations of These .procedures will work, however,
none of them has emerged as markedly superior.
Attention to the use of a reliable batch of PEG, good
serum, and the like may improve reproducibility, but the
barrier to increasing the number of hybrids may be a
-biological rather than a technical problem.
1.4 Why we are studying ADH
Class I human liver alcohol dehydrogenase (ADH)
dimeric isoenzyines are made up of the following subunit,
a A2 and Y2 whereas' 2 are found to be
predominant in the' orient, thus earning the name of
atypical. The Km and k cat of each purified atypical
isoenzyme are well studied, each can be fitted into
either one of two simple Michaelis-Menten system, a low
8affinity system or a high affinity system. From the
enzyme kinetics, it is proposed that /32 subunit
contributes significantly to the low affinity activity
wherever it is present whereas the high affinity
activity was contributed by a or Y subunit. The
subunits differ from each other only in one or several
amino acids in their peptide chain. So these atypical
isoenzymes offer a good model in studying the subunit
interactions. Monoclonal antibodies react specifically
against each subunit can serve as a useful tool in
studying these interactions.
Different individuals of the same race may have
different isoenzymes, and each race has its own
predominant class of isoenzymes. The genetic factors
governing this distribution is unknown, so the
identification- of genes of each isoenzyme may help to
.elucidate this hereditary mystery. Monoclonal
antibodies are a useful tool to identify the genorne.
Will different genotypes of isoenzymes change their
dominance or recessive expression once the hosts are in
different diets, in different climate or environment, or
having some -diseases (e. g. hepatitis)? An interesting
problem arises whether alcoholic addicts can induce
specific isoenzyme subunit to express so that they can
tolerate the* gradual increase of alcohol intake.
Monoclonal antibodies carrying special markers when
taken inside the body of the host before and after the
r+handes may answer all these- questions.
9CHAPTER 2 PRODUCTION OF MONOCLONAL ANTIBODIES TO
HTIMAN LIVER ALCOHOL DEHYDROGENASE
This chapter will describe the whole process in
the production of monoclonal antibodies to human ADH.
In the first part of this chapter, the myeloma cell line
being used, the establishment of the specific screening
assay and also the properties of immunogen (ADH) used
will be discussed. 'The rest= of the chapter will
concentrate on the whole process of immunization, fusion
steps, hybridoma propagation and cloning, and finally
the establishment of hybrid cell lines.
2.1 M,Yelema Cell Line
Myelomas are the tumours caused by malignantly
transformed antibody-secreting cells. Though
spontaneous myelomas are rare in normal mice, however,
it was accidentally discovered that peritoneal irritants
could cause development of myelomas in BALB/c mice
(Merwin and Redmon, 1963). Subsequently it was found
that mineral oil or pristane were potent inducers of
myeloma in BALB/c mice (Potter, 1972). So a large
number of mouse myelomas are isolated and developed,
but only a few of these have been successfully adapted
as continuous tissue culture lines (Horibata and Harris,
1970).
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2.1.1 Enstures of myelona cell lines
Of all these myeloma cell lines, not all of them
are suitable candidate as the fusion partner in
hybridoma construction, the right one should have at
least the following features:-
(a). the presence of drug resistance markers for
selection against unfused myelomas
(b). lack in the production of undesired heavy and
light immunoglobulin chains
(c). stability of the hybrids formed by fusion with
the myeloma cells.
It is also very important that the selected
myelomas do not produce heavy or light immunoglobulin
chains, or both of them, otherwise, myeloma's heavy and
light chain will combine with spleen's desired chains
producing hybrid-antibodies, thus decreasing the fusion
efficiency (Cotton et al., 1973).
The myeloma cell lines presently employed are
derived from the BALB/c mouse myelomas MOPC 21 or MPC 11,
both of them meet the requirements listed above. Many
hybridomas were successfully derived by employing the
descendants of either of these 2 lines.
2.1.2 Our choice of myeloma cell line----- NS-L
The myeloma cell line that we used is termed
NS-1 (P3-NSI/1-Ag4-1), derived from X63, which in turn
derived from MOPC 21 line. NS-1 cell has 65 chromosomes,
producing short K chains but are degraded internally and
not secreted.• It is capable of growing in the presence
of toxic concentrations of 8-azaguanine( 20 ugml)
or 6—thioguanine, due to the deficiency of enzyme
hypoxanthine-guanine-phosphoribosyl transferase (HGPRT)
for the purine salvage pathway. Because of this, the
toxic drug, 8-azaguanine, cannot be incorporated. This
line has proven to be more popular than those non-
immunoglobulin chain producing cell lines, e.g. P3-X63-
Ag8.653 (653) as it is relatively easy to fuse.
In our experiments, 8-azaguanine was frequently
added to myeloma NS-1 cells in a final concentration of




Being a HGPRT-deficient cell line, NS-1 is HAT
sensitive (Littlefield, 1964). The selection system
generally adopted relies on blocking the main nucleic
acid synthetic pathway using folate antagonist,
aminopterin. This prevents the de novo synthesis of
purine via inosine monophosphate and also prevents the
methylation of deoxyuridine monophophate to
deoxythymidine monophosphate( Fig. 2.1). Cells
therefore become dependent on extraneous sources of
12
Fig. 2.1 Pathways of nucleic acid synthesis











purines and thymidines which are used to synthesize
nucleic acids via the alternative salvage pathways.
Hypoxanthine can be converted to inosine monophosphate
by the enzyme HGPRT and thymidine can be phosphorylated
by the enzyme thymidine kinase. Myeloma deficient in
HGPRT can only be rescued by fusion with an immune
splenocyte supplying the HGPRT genome.
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2.2 The Screening Acciv
The whole process of producing monoclonal
antibodies demands fast, sensitive and' reproducible
screening assays to identify clones with desired
reactivity from those making irrelevant immunoglobulins.
Of all of the standarized screening methods, they can be
grouped into 2 classes. One of these detects antibody
molecules secreted by the hybridomas into the culture
media, examples include radioimmunoassay (Buttin et al.,
1978, Kennet et al., 1978) immunoelectrofocusing
analysis (Kohler and Milstein, 1976 Buttin et, al.,
1978) Enzyme-linked immunosorbent assay (ELISA)
(Moudallal et al., 1984) etc.. The other detects
antibodies produced by the hybridomas at the cellular
level, such as the plaque-forming cell assay (Kohler and
Milstein, 1976 Andersson et al., 1978) and the rosette-
forming assay (Dominique et al., 1979). We have
selected ELISA for this work because it is simple and is
capable of handling several hundred samples at the same
time. Furthermore, the possibilities of automation is
an added attraction.
2.2.1 Principle
The detection of desirable antibodies in culture
supernatant is performed by incubating culture
supernatant with pre-immobilized antigens on a
microtiter assay plate, followed by washing and addition
15
of anti-immunoglobul in antibody conjugated with enzyme,
the subsequent addition of chromogenic substrate results
in. detectable colour changes which is quantitatively
proportional to the amount of antibodies in the original
culture media.
2.2.2 Materials
Carbonate-bicarbonate coupling buffer, pH 9.6: 2.9 gm of
NaHCO3 and 1.6 gm of Na2CO3 were dissolved in
1 litre of distilled water.
Bovine serum albumin (BSA) in phosphate-buffered saline
(PBS): 0.1% BSA was dissolved in PBS.
Washing buffer, pH 7.4: This is made up of PBS, EDTA
(0.1%), .Thimerosal (0.01%) and 'Tween 20 (0.05%).
Enzyme-labelled second antibody: goat anti-mouse
polyvalent immunoglobulins peroxidase conjugate
diluted in washing buffer.
Chromogenic substrate: 80 mg of o-phenylenediamine and
40 ul of 30% H2O 2 were dissolved in 100 ml citrate-
-phosphate buffer, pH 5( Substrate should be
prepared fresh and cannot be stored).
Titertek microtiter immunoassay plate: 96 well flat
bottom, PVC.
Spectrophotometer: Titertek Uniscan microelisa autoreader
2. 2. 3. Procedure
One hundred microliter of ADH at a concentration
16
of 30 ug/mi in coupling buffer were dispensed into wells
of mi.crotiter plate and incubated at 4°C overnight.
Overnight incubation allowed soluble antigens to adhere
passively to plastic without alteration of its distinct
antigenic structure. Antigen-precoated plates when
stored at 4°C for over a month, were still found to be
workable. The antigen supernatant collected from wells
of coated plates could be reused once more to coat
another plate as antigens added to wells were already in
excess.
When carrying out the immunoassay, the plates
were inverted and flicked to remove antigen supernatant,
washed once with PBS, flooded the whole plate with
0.1% BSA in PBS, and stood at room temperature for
1 hour to allow BSA to saturate all the empty sites.
Plates were then taken out and washed twice with PBS,
and were made dry by brisk inversion on tissue paper.
Droppers connected to air pump were used to suck the
remaining water moisture. 100ul of culture supernatant
were dispensed into each well. Antiserum collected from
mouse just before fusion served as the positive control.
Several negative controls were desirable and they
included rcyeloma culture media, washing buffer and
unrelated antibodies. The plate was incubated at 37 °C
for 2 hours.
After incubation, plates were washed by
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dispensing about 0.2 ml of the washing buffer into each
well, 5 minute incubation allowed buffer to wash out the
non-specifically absorbed antibodies. Two more washes
were required and plates were made dry. 100ul of
enzyme-labeled secondary antibody were dispensed into
each well and was allowed to,'.-incubate at 370C for
1 hour.
After 3 washes, 100 ul: of freshly prepared
chromogenic substrate were added to each well and
allowed to react for 15 minutes at room temperature.
The enzyme-substrate reaction was then stopped by
addition of 50 ul of 4 M H2SO4. The plate was then read
at a wavelength of 492 nm in a Uniscan photometer, the
reference well against which the zero value was set
(blank) was given by reading the well with 0.1% BSA ir.
PBS.
All the values from negative controls were
combined to obtain arithmetic mean {X} and the standard
deviation (SD). For better precision,. sample wells
considered as positive were those with optical density
greater than. three standard deviations from the
'negative' mean.
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2. 3 Immure jgarl-----ATfi
2. 3. 1 Human Liver A1thhol Dehvdroaenase
The immunogen is human liver alcohol
dehydrogenase, a class of NADH-dependent enzymes that
catalyze the interconversion of.. ethanol and other
alcohols to the corresponding aldehydes. Certain
secondary alcohols and sterols can be used as substrates
also.
Human alcohol dehydrogenases are oligomers and
can be -resolved into more than fifteen subunits.
Electrophoresis of human tissue homogenates on starch
gel reveals multiple bands when stained for activity
with ethanol as the substrate (Smith et al.., 1971,
1972). The number of forms and their migration relative
to one another vary with individual, depending on the
particular tissue examined and the age of donor. This
suggests that developmental and genetic origins may play
A _qianificant role.
The liver contains by far more ADH activity than
any other organ. While other tissues appear to contain a
smaller number of isoenzymes, the liver has a full
complement characteristic of that individual.
Therefore, it is logical that liver being served as the
source to isolate and characterize isoenzymes.
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2.3.2 properties of human ADH
Human liver ADH was first isolated by von
Wartburg et al'. in 1964 and fractionated into
chromatographically distinct forms by Blair and Vallee
in 1966. Meanwhile, three major molecular forms of
horse liver ADH were found to be the dimers of
dissimilar polypeptide chains. This led Schenker etal.
in 1971 and Pietruszko et al. in 1972 to conclude that
similar considerations might also pertain to at least
some of the molecular forms of human liver ADH then
known.
Affinity chromatography (Lange and Vallee, 1976)
has enabled the isolation of large quantities of human
ADH and this has resulted in the recognition of the
remarkable molecular heterogeneity of this enzyme and
the differentiation of its multiple forms by physical,
chemical, immunological, and enzymatic criteria.
Some of physical and chemical properties of
human ADH are listed in Table 2.1. Properties of the
horse enzyme are listed together for comparison
Table 2.1 Physical and Chemical properties of
crude Human liver and Horse liver ADH

























2.3.3 Classes of human liver ADH i soenzvmes
Three major classes of human ADH isoenzymes are
now known.. Their separation is based on their different
properties and are summarized in Fig. 2.2.
As Class II and Class III' comprise only a small
portion of- isa.enzymes in oriental human' liver, so all
the efforts are spent in purifying and studying Class I
of or ental human liver ADH.
2.3.4 Lsoenzymes of C1 ass I oriental human liver AD
All constituent forms of Class I bind to the
potent specific inhibitor, 4-methylpyrazole (Li and
Theorell, 1969), which led to the design and synthesis
of 4-[3-(N-6-aminocaproyl) aminopropyl]-pyrazole
(CapGapp), the derivative immobilized on Sepharose 4B
(Lange and Vallee, 1976). All isoenzymes of this class
migrate cathodally on starch gel electrophoresis at
pH-7.7 and 8.6.
Class I human ADH consists of homodimers and
heterodimers of three polypeptide chains designated a
and P (Smith et al., 1971, 1973). In addition
both the Y and more recently the chains are known to
occur in subforms, that is, as and 2 and as and 2
So facet has known that the compositional and enzymatic
properties of all these isoenzymes are quite similar.



















(from Vallee et al.f 1983)
The constituent terms of Class I homodimers and
heterodimers seem to be formed by random combination of
subunit chair
5g subunit is only found in oriental population
so far, thus making new combinations of constituent
forms of Class I isoenzyme. They are thus named variant
form, or atypical ADH, exhibiting characteristic
activity under different pH; migrating far more
cathodally in starch gel electrophoresis; having much
higher specific activity; remarkably insensitive to
modification by iodoacetate, etc.
Based on the analysis of tryptic peptide maps of
this variant form and on the typical form, the variant
is attributed to the genetic replacement by a histidine
of a cysteine corresponding to Cys-47. Yet the
relationship of. this amino acid replacement to the
differences in enzymatic behaviour between typical and
atypical forms is unknown but is reminiscent of amino
acid replacements and their functional consequences in
abnormal hemoglobins.
2.3.5 Reasons of producing monoclonal__antibodles_against ADH
Different populations have their own distinctive
forms of combination of classes and isoenzymes of ADH,
and each individuaX has its own. combination pattern.
Whether the occurrence of these variations are
24
genetically determined is an open question.
The much higher specific activity of the
atypical form, found in a large proportion of an Asian
population, has been suggested to be related to the
intolerance of this group to alcohol intake when
accompanied by the flushing r-eaction. The latter in
turn is thought to be related to, the concentration of
blood acetaldehyde (Wolff, 1972 Zeiner et al., 1979).
Alternatively, the accumulation of acetaldehyde in the
blood of such individuals has been attributed to their
def iciency' in a form of aldehyde dehydrogenase which has
a low Km and reduced capacity to metabolize acetaldehyde
(Harada et al.) 1980). The available data could support
either view. To resolve this, further studies on
structure and enzymatic properties of all ADH isoenzyme
forms are required. In this regard, the best probe seems
to be a monoclonal antibody specifically against one of
the i s oenzyraes.
It is generally assumed that the function of
alcohol. dehydrogenases is the oxidation of ethanol, but
the exceptionally broad substrate specificity of the
crude human liver ADH has been documented to include
many other metabolites such as drugs, poisons that
contain alcohol and aldehyde groups. Among these are
digitoxigenin, gitoxigenin, methanol and ethylene glycol
(Frey and Vallee, 1979, 1980). All of them bind on the
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same substrate binding site of ADH and are then
converted to the corresponding oxidized products. So
ADH serves ter remove the circulating alcohol and the
above named drugs, however, the efficiency of removal of
these alcohol related chemicals seem to vary from one to
another. Hence, different forms of isoenzymes seemed to
account for this variable tolerance to-alcohol and drug
intake. Besides the genetic basis of isoenzyme factor,
can other factors such as environmental ones (e. g. diet,
climate, or disease, etc.) contribute to variable
response? Can the cooperativity of subunits be affected
in this way?
By isolating the enzyme from human source, a
probe is needed to study not only the oxidation of
alcohol and related drug, the pathology of alcohol
metabolism in man, but also the regulation of subunit
cooperativity. Monoclonal antibodies directed against
ADH seem to be a satisfactory candidate.
2.3.6 Purification of Class I Oriental=type of human An-H
The crude human alcohol dehydrogenase used in
this study was kindly supplied by Dr. Keung's group
(Department of Biochemistry, C. U. H. K.). The
purification scheme shown in Fig. 2.3, basically
followed those of Lange and Vallee (1976) with some
modifications. The crude enzymes, as supplied to us,
was dissolved in 0.01 M Tris-phosphate buffer, pH7. 4.
Fig. 2.3
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2. 4 TMMIINTZATION
To obtain a high yield of antigen-specific
hybridomas, an essential step is to obtain an optimal
immunization scheme. Immunization protocols vary widely
depending upon many factors: whether the antigen is
soluble or particulate (e. g. cell surface antigen opiate
receptor on neuroblastoma-glioma hybrid cell line
NG108-15), the known degree of immunogenicity of the
antigen, the degree of purity of the antigen and the
actual amount of antigen available. In addition, the
desired class of monoclonal antibody to be made* is also
critical in determining the immunization protocol and
source of antibody-producing cells.
The immunization procedures for hybridoma
production invariably consist of two parts:-
(a). a series of 'pre-immunizations' to stimulate
antibody production together with the
enhancement of proportional number of committed
memory B-cells
(b. a 'pre-fusion' booster 4 days prior to fusion.
2. 4.1 Priamry pre-immunization
There is considerable evidence that it is not
the mature antibody-secreting plasma cells which fuse to
give. productive hybrid.omas, but rather it is the
B-lymphocyte cell, recently derived from the
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"memory" or resting B-cell population which have been
triggered by-re-exposure to antigen. Thus, the purpose
of the pre-immunization is not to stimulate antibody
production, although this is a necessary by-product, but
rather to increase the proportion of committed memory
B-cells.
2. 4. 1. 1 Use of ad juvant
The first injection of antigen should be given
in a highly aggregated form, because soluble monomeric
proteins in their native state are poorly immunogenic
and tended to induce tolerance (Dresser, 1962). As ADH
is a water-soluble protein, Freund's complete adjuvant
(Hebert, 1973) was employed as non-specific classes of
immunoglobulins were desired( The nature of adjuvant
affects the class of antibody produced).
2.4.1.2 Properties of adjuvant
Adjuvants are substances having the property of
potentiating the humoral antibody response.to injected
immunogen (Whitehouse, 1977). This concept was derived
from the observation that high antibody titers are
stimulated when an antigen is injected into tuberculous
granulomata than are they injected at nontuberculous
sites (Dienes and Schoenheit, 1930). This provides the
evidence that intracellular bacteria may play a
stimulatory role in antibody formation. Finally, Freund
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and co-workers developed an adjuvant (Freund at al.,
1942), which to this day remains the most potent tools
available to the immunologists.
The complete Freund's adjuvant (CFA) contains 9
parts of mineral oil to 1 part of detergent with the
incorporation of heat-killed MY-cobacterium tuberculosis
( 0. 5mg/ml) (Freund et al., 1942). The detergent
(usually Arlacel A) contains a high level of both
hydrophilic and lipophilic groups, thus facilitating
dispersion of the oily and aqueous (immunogen) phase
and allowing the formation of a stable emulsion
(Hurn et al., 1980).
The adjuvants have the following functions:-
the release. of immunogen from the site of(3).
injection is slowed by incorporation into an
oily emulsion. This leads to a substained
release from a depot at the injection site,
where labile immunogens are also protected from
breakdown by tissue enzymes. Any direct toxic
effects of the immunogen on the recipient will
also be minimized.
Adjuvants have a stimulatory effect on(b)
reticuloendothelial cells, attracting a local
infiltration at the injected area by mononuclear
cells and stimulating phagocytosi.s by macrophages
presumably by presenting soluble immunogen in a
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particulate or partially aggregated form.
Adjuvant-treated macrophages with antigen
inoculated into histocompatible recipients give
rise to a higher antibody response than transfer
of macrophages containing antigen alone (Unanue
pt al., 1969).
(c) It has been shown that adjuvants- can induce an
increased circulation of lymphocytes through
lymphoid tissues in the drainage area (Frost et
al., 1973). Macrophages being important for the
initiation of these lymphocyte traffic changes
(Frost ,et al., 1974}. The increased flow of
cells in regional lymph nodes is likely to allow
greater contact between antigen and antigen-
reactive cells, thus facilitating increased
antibody production.
2.4.1.3 Antigenic emulsion reEaratior
Vials of complete Freund's adjuvant was
obtained from Sigma. It is important that the vial be
shaken to resuspend the mycobacterium prior to use. It
is traditional- to mix equal volumes of antigen (in
aqueous solution) and adjuvant to form an emulsion. The
adjuvant was' first added into a vial bathed with ice,
then small amount of antigen solution was- injected into
adjuvant with the help of a plastic syringe and an 18
gauze needle. To form the emulsion, the total content
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was sucked up and down the syringe for at least ten
times. The final mixture should be in the form of a
thick and creamy emulsion.
2.4.1.4 Route, Site- Dosage of Innoculation
There are several routes of injection of
antigen, such as intravenous, intramuscular,
subcutaneous, intraperitoneal, intradermal, intra-
articular and intranodal. Using oily adjuvants, this
could be narrowed down to only subcutaneous with a view
to minimize discomfort. Yet if the injection manner
were not done well, subcutaneous injection could still
lead to ulceration (Hebert, 1973).
The area of inoculation might be important.
This should be done near the lymph nodes to increase the
likelihood of the antigen passing through the lymph
nodes. Several sites could be chosen, for example, the
dorsal sides of the lower limbs and the neck. Other
sites' could also be chosen, however, they usually caused
more discomfort to the animal. Moreover, the chosen
site should also be inaccessible to the mouth,
otherwise, this would promote the leaching out of
antigen from the injection area. In this study, the




.L LAW.L Gu j71LJ.D/ u mice are usually chosen as the
source of immune spleen cells, primarily because the
myeloma cells used for fusion are of BALB/c origin
(syngeneic) and problems of histocompatibility are
avoided when hybridoma cells are grown subsequently as
ascitic tumours. Mice were usually immunized at 6 weeks
of age, the time when their immune system was matured.
2. 4. 1. 6 Dosage of i mmun o en
0.4 ml of ADH in adjuvant emulsion was injected
per mouse, that is, 0.2 ml was injected subcutaneously
to each limb. Originally, 1 mg/ml of ADH was mixed with
an equal volume of CFA, therefore, 0.4 ml of ADH in
adjuvant emulsion contained 200 ug of ADH.
2.4.2 Secondary, pre- mmunizatiQ
In the second pre-immunization, the procedur
was the same as before, except that the adjuvant uses
was incomplete (that is, without the tubercle bacilli)
This was to prevent hypersensitivity of the host to thi
bacteria.
2.4.3 As saY of antibodyt jeer
Mice immunized with ADH-Freund's emulsions were
bled 7-10 days after the second booster. Mice were
first illuminated with a strong spot light until their
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ears became stiffen and flapped over on their heads
closely. At'this time, peripheral vasodilation occurred
and the blood circulated quickly. A cut was made on the
ventral side of its tail and blood would drip out
smoothly and was collected in a microcentrifuge tube.
About 1-1.4 ml blood can be obtained this way. The
wound was then wrapped with clean cotton wetted with
70% ethanol (EtOH) to avoid more leakage of blood and
bacterial infection.
Blood was allowed to clot at room temperature
for 1.hour. A toothpick was then used to `ring' the
clot to separate the clot from the side of the tube.
The whole sample was then transferred to 4 0 C overnight.
Next day, the clot would retract quite well. Only serum
was then taken out for centrifugation. The supernatant
after centrifugation was then pipetted out.
The serum samples of several immunized mice were
then taken for ELISA immunoglobulin screening. Several
duplicate dilutions of the tested samples were usually
done so that false positives could be eliminated. As a
control, normal mouse serum was also performed
simultaneously.
2.4.4 Last Booster
In a group of immunised mice, the one showin
the highest titer of antibody response was selected fo
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fusion. But one must bear in mind that the highly
immunized mouse might then be in a hyperimmunized state
and could no longer tolerate the higher dose of last
booster, so another mouse showing the second high
antibody titer should also be boostered at the same time
for the sake of insurance.
The purpose of the last booster. was to stimulate
resting B cells into a vigorous blast transformation,
so a new approach was taken, intrasplenic immunization
( Spitz et al., 1984). With the intrasplenic route
of injection, a localized high concentration of antigen
in the target organ was produced with very little
antigen. But more importantly, it maximized the number
of specific B cell blasts in the spleen by direct local
antigen stimulation. Uptake and elimination of antigen
in other parts of the body, as was the case with other
routes of injection, was minimized by this procedure.
So this offered an additional advantage to availability
of. little antigens.
The suggestion of a direct effect of a localized
high concentration of antigen in the spleen was
supported by results of experiments in which a good
yield of specific hybridomas was obtained by immunizing
spleen cells in vitro with very little antigen
(Luben et Al., 1982).
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2.4.4.1 Intrasplenic Immunization
Approximately 20 ug of ADH was dissolved in
50-100 ul PBS. ..A 1/2 x 27 gauge needle fitted to a lml
syringe was used for injection and the highly immunized
mouse was anaesthetized with the use of ether. The
mouse was placed on its right side. The abdomen was
swabbed with 70% EtOH. A skin incision 1. 5 cm long was
made and the spleen was exposed. The organ was
exteriorized by gently lifting of its lower pole. A
needle was then inserted into the spleen and ADH was
inoculated as the needle was being pulled out. This
ensured- that the antigen would distribute through most
of the spleen. The spleen was carefully pushed back into
the peritoneal cavity and the wound was sutured.
After 4 days, the spleen was taken out for
fusion. It is, usually found to be enlarged compared
with mice immunized by other means. It seems that
either the 100 ul of ADH antigen might have caused the
swelling of spleen, or the spleen was undergoing
vigorous blast transformation.. The latter case seems to
8
be more reasonable, since about 1.3 x 10 splenocytes
per spleen can be obtained from the intraplenic
immunization, while only 10 B splenocytes was obtained by
other route of immunization.
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2.4.4.2 Intravenous booster
4 days before fusion, the mouse showing less
antibody response was illuminated to dilate the
peripheral tail vein. 400 ug of ADH suspended in 0.5 ml
of PBS was then injected. A cotton wool wetted with 70%
EtOH was used to wrap,the wound. Then the mouse was
left alone until the day of fusion.
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2. 5 FUSION
The 'actual procedure of fusing immune
splenocytes with myeloma cells *involved only 2 hours.
Yet this critical period determined the efficiency and
effectiveness of the whole. process of antibody
production.
The fusogens being, used had changed
dramatically since Kohler and Milstein (1975) used
Sendai virus for their first experiment. The technique
was satisfactory, but it required the handling of virus
culture and the' hybridoma seemed to yield more IgM
antibodies (Fazekas et al., 1980). Polyethylene glycol
(PEG), a chemical fusogen and an agglutinating agent
for plant protoplast fusion, was first introduced by
Kao and Michayluk in 1974. Its initial use as a fusogen
for hybridoma work was introduced by Gefter in 1977.
Polyethylene glycols of different molecular
weights and commercial sources had been tested by
Fazekas in 1980 for their efficiencies in fusion. All
low molecular weight polyethylene glycols were proved to
be less effective, and some batches were found to be
toxic. The high molecular weight forms had their
drawback as they were too viscous to be pipetted, even
at 45OC. In all of the products, PEG 4000 from Merck
(Cat No. 9727) proved to be the best. In another series
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of tests( Davidson at. al., 1976 Steplewski at- -al.,
1976 Fazekas et al. 1980), the optimal concentration
of PEG was determined to be about 50% while the optimal
molecular weight depended upon the fusion technique
used. With monolayers, PEG 1000 proved to be optimal
and with cells in suspension PEG 4000 would do better.
As we did fusion in suspension, so Merck PEG 4000 was
used.
2.5.1 Cellular mechanism of fusion
Membrane fusion consists of 2 distinct stages:-
(a). Cell agglutination, during which the plasma
membranes of adjacent cells are brought into
close proximity
(b). The formation of cytoplasmic bridges between cells,
followed by osmotic cell swelling and heterokaryon
formation.
PEG is slightly negatively charged in aqueous
solution. When PEG is added, the surface potentials of
membranes are markedly decreased (Maggio-et al., 1976)
and causes charge neutralization throughout the
membranes. CeIl agglutination then follows. One minute
after exposure of cells- to PEG, lipid probes spread
from one plasma. membrane into the other (Wo j c i es zyn et
Al., 1983), while no intermixing of membrane protein can
be detected.
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PEG is also hydrophilic and can bind water
only at a concentration of at least 35% by weight
(N.B. we used 50% PEG), so dehydration together with
depolarization factors appear to play a role in PEG-
mediated fusion (Knutton et al., 1979 Krahling, 1981).
After initial PEG treatment, the cell mixture
was diluted gradually in serum-free medium to a
concentration of 1-2%, at this stage, intercytoplasmic
communication began to take place (Wojcieszynn et al.,
1983). Cytoplasmic bridges could -be observed by
electron microscope (Maul et al., 1976 Clark et al.,
1978 Knutton, 1979). Water-soluble cytoplasmic
proteins only diffused from one cell to the other when
PEG was removed and was completed after 4 hours
(Rabinovitch et al., 1981 Wojcieszyn et al., 1981,
1983).
2.5.2 Preparation of fusogen
The day before fusion, 10 gm PEG was weighed and
put into a screw-capped 5 ml reagent bottle, and
autoclaved (15 lb/in2, 20 min) to sterilize and liquidfy.
While the PEG was still hot, an equal volume of plain
culture medium was added. The mixture was then vortexed
quickly to ensure that the PEG would not solidify.
Several drops of sterile 7.5% bicarbonate solution
was added to PEG mixture to adjust the pH until its
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colour changed from acidic yellow to a slightly neutral
colourless appearance. The PEG fusogen was stored at
40C until use.
2.5.3 Preparation of spleen cellE
Instruments needed were medium-sized scissors,
fine scissors and fine forceps They were autoclaved
beforehand.
The blood of the mouse used for fusion was
collected before the removal of its spleen. The serum
was then assayed for its antibody titer on the following
day to ascertain the immune status of the animal. The
animal was killed by cervical dislocation and then
flooded with 70% alcohol to sterilize the outer layer of
the skin and hair. The abdominal cavity was dissected
with a sterile pair of scissors. Care was taken to avoid
damaging the gut. The spleen was removed and placed
into a sterile dish containing 10 ml PBS with double
strength of antibiotics. The spleen was further washed
twice with plain RPMI medium containing double strength
of antibiotics.
The spleen was then placed.into a sieve with,
a sterile disposable dish underneath. The dish was then
half filled with plain medium. After cutting the spleen
into pieces, a sterile syringe plunge was applied to
grind the spleen to release single cells. The cell
suspension was then taken for a quick centrifugation
(800xg, 10 seconds) to remove any large cell clumps and
debris. Then it was recentrifugated (400xg for 5 min.),
washed twice with plain medium, and counted. Viability
was usually greater than 85%. If not, the efficiency of
fusion would be low.
Erythrocytes were not generally removed as it
was found that treating spleen cells with 'lysing
solution' not only lyses the erythrocytes but would also
cause substantial damage to the spleen cells ultimately
decreasing the fusion efficiency.
Typically, a mouse spleen would yield
approximately 10 nucleated cells.
2.5.4 Preparation of Feeder cells
Feeder cells were used and they are splenocytes
from normal BALBc mice. Feeder splenocytes were first
treated with 1lysing solution' so as to remove the
erythrocytes, the undesirable accompanying cells.
2.5.5 Preparation of myeloma cells
Myeloma NS-1 cells were maintained in two 75 cm
culture flasks, and were kept in exponential growth for
1 week before fusion. 24 hours before fusion, the cells
were replenished with fresh medium, and adjusted Do a
cell concentration of 2 x 10 ml. The next day, it
would, become confluent. As a confluent flash contained
about 4—5 x 10 csllsnilt so two confiusnt j.ladies,
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each containing about 25 ml culture medium, would yield
about 2-2.5 x 107 myeloma cells. This is more than
sufficient for •one fusion experiment.
As myeloma cells slightly adhered to the bottom
of flask surface when at rest, so the flask should be
shaken gently while collecting the cells. The
collection and centrifugation of myeloma cells were done
at the same time with that of the immune spleen cells.
The myeloma cells should be washed twice in plain medium
so as to remove any FBS. Then they were taken for cell
count.
2.5.6 Fusion of Cells in Suspension
At this stage, several things should be done,
such as warm up of fusogen and PEG solution to 37°C with
an insulated beaker half filled with water at 40 °C
All the spleen cells (.108 cells) and mvelorna.
cells (one-tenth of spleen cell number, 107 cells) were
added and mixed in a 50 ml conical tube, plain medium
was added to a volume of 30 ml. The cells were then
spun down at room temperature for 6 minutes at 400x:g.
The pellet was resuspended once more in about 3 ml of
medium and was then taken for centrifugation again, as
centrifugation of cell suspensions in large volume
would result in uneven packing of two types of cells.
Uneven mixing of cells would definitely decrease the
43
chance of fusion of myeloma cells and spleen cells
All the supernatant above the mixed cell pellet
was then aspirated out'with long pasteur pipette. The
conical tube was then tapped gently to dislodge the cell
pellet and placed inside an `insulated beaker'
containing water at 40 C. 1ml of warm PEG solution
was added evenly dropwise within ,1 minute, the tube was
tapped gently throughout the whole adding process to
allow PEG to mix well with the cells. The tube was left
in the bath for 1 minute, allowing time for PEG to act
on the membranes of both cell types. 2 ml of plain
medium was then added dropwi s e and this served to stop
the fusion process by diluting the PEG. The adding
of medium should be slow initially so that the
disturbing of fragile cells was minimized. Gentle
tapping of the tube was being done throughout the whole
process.
10 ml of plain medium was then added within
3 minutes to dilute the remaining PEG. Afterwards a
feeder cell suspension( 44 x 108} was then added to
the hybrid cell suspension. The total mixture was then
centrifugated at 200x.8 for 10 minutes. As the hybrids
were in an extremely fragile stage, larger
centrifugation force would definitely be undesirable.
After centrifugation once, the cells were
suspended extremely gently in 30m1 culture medium with
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20% FBS. Cells were then dispensed into three 9 -well
culture plates with multi-channel autopipette, each well
containing 100 -ul and 5 x 105 feeder cells. The plates
were put to an incubator at 3700 and was left there
undisturbed for 24 hour.
2.5.7 Some comments on the techniques used in fusion
2. 5. 7. 1 Removal of Erythrocytes
The erythrocytes present in the spleen used for
fusion were not lysed in my practice, but most of the
investigators lysed them on the assumption that an
increased collision frequency between splenic
lymphocytes and myeloma cells which in turn would
increase the fusion efficiency.
Yet from my experience, the lytic process would
not only lyre the erythrocytes, but might also cause
substantial damage to' the splenocytes and ultimately
led. to a decrease in the fusion efficiency. Though
Gey's hemolytic medium was recomended to have greater
degree of protection of white cells than do other lytic
reagents (Zola et al., 1982), yet their usefulness in
fusion experiments has yet to be determined.
2.5.7.2 Splenocytes preparation
In order to maximize the fusion efficiency and
to increase the yield of hybrid cells, splenocytes used
for fusion or as `feeders' should be grounded gently on
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gauze so as to preserve cell viability and function.
The presence of fibroblasts in the culture would
certainly outgrowth the hybridoma cells and this should
be avoided.
2.5.7.3 Presence of Hepes in medium during fusion
Hepes was reported to be toxic to cells
permeabilized by PEG in tree 'fusion step (Kennett, 1979).
Plain medium without FBS is not a well-buffered system
and if it is exposed to the atmosphere during fusion,
CO2 will escape and the drastic increase of pH can
cause cell death. So Hepes-buffered culture medium was
used in the fusion procedure, the resulting fusion
efficiency was still found to be acceptable.
2.5.7.4 Polyethylene glycol
The concentration of PEG used was approaching
toxic level and therefore the time of exposure and the
concentration employed were actually a compromise
between increased fusion efficiency and toxicity.
Therefore, the time of exposure of the cells to PEG
should be well controlled so as to get a higher yield of
the hybridomas.
2. 5. 7. 5 Aria+ nn of DMSO to fusopen
The addition of 10% dimethylsulfoxide (L)Mbu) 710
the PEG solution (Norwood et al., 1976) was reported to
enhance fusion efficiency. Most groups acknowledged the
benefit of adding of DMSO (Nesterwoudt et al., 1984
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Fazekas at al., 1980) Provided that other fusion
conditions were optimized. It facilitated the removal
of PEG after fusion and perhaps buffered the potentially
damaging rapid osmotic changes in the actual fusion and
subsequent dilution steps.
DMSO had been 'found to-promote the entry of
Hepes buffer into cells resulting in cytotoxicity
(Kennett, 1979). As we used Hepes in our culture medium
so DMSO is not added to the fusogen in our work.
2.5.7.6 Feeder cells
The biological mechanisms affecting the growth
of fused cells into colonies of hybrid clones as well
as the cloning efficiency of a single hybridoma cell
were not well understood (Kohler, 1979). Many
investigators had found that the addition of feeder
cells could greatly improve the yield of hybrids, in
some but not all experiments (Fazekas et al., 1980
Brodsky, 1979 Oi et al., 1980). To summarize the
views, feeder cells are not necessary, if conditions
are ideal, but if one of the many factors influencing
the growth of hybrids after fusion is not optimal,
feeder cells can help to make up for the deficiency.
The actual mechanisms by which feeder cells
could promote the growth of hybrids are unclear. Some
speculated that they provided cell-to-cell interaction
(Hammerling, 1978 Lernharddt, 1978), whereas others
47
thought that they may secrete soluble growths factors
(Astalki et al., 1980)
Besides .splenocytes, alternative sources of
feeder cells are thymocytes (0i, 1980), peritoneal
macrophages (Faz ekas et al., 1980) and irradiated human
fibroblast (Brodslyy et al., 19 79.). Human endothelial
culture supernatants were also reported to have strong
growth-p r0motion activity (Astaldi et al., 1980).
Splenccy es were used in our experiments. We
ham. attempted not to use feeders and the result
obtainer was unsatisfactory Of all the cell source,
splenocytes are the easiest to prepare. Peritoneal
macrophages had also been tested for their promoting
ability. They functioned well. However, the yield of
peri Uonealacrophages is. rather low in normal mice
whereas mice in5ected with pr. istane as a stimulus have
given rise to a very heterogenous population of
macrcp gage. Thus peritoneal macrophages are not
normally used as feeders in our work.
2.5.7.7 Serum
Serum was excluded foem culture medium during
fusion as serum was reported to delay cell adhesion
(Maroudas, 1975) and Would produce protein precipitation
when PEG is added. (Zola et al., 1982).
48
2.6 Propagation of Hybridoma
The propagation of hybridoma was the second most
difficult and• complex stage in the whole process of
production of monoclonal antibodies. Many interesting
clones could be lost during this period. The success of
producing a good monoclonal antibody seemed to be
determined at this point more than others.
The objectives of this stage were quite simple
to state, but difficult to achieve. Firstly, to place
the fragile and delicate hybrids together into the
culture medium which would allow them to grow.
Secondly, to prevent growth of unfused cells and
thirdly, to select out the hybridomas secreting the
desired antibodies from a large population of non-
cArr r
2.6.1 Difficulties encountered by infant hybrid
2.6.1.1 Unpreventable chromosomes lose
At this stage, the cultures are unstable in
several different ways. The fusion products themselves
are genetically unstable. A mouse diploid cell has
40 chromosomes, so that a nucleus formed from the fusion
of two such cells has 80 chromosomes. Such a nucleus is
unstable and chromosomes will be lost. The losing
tendency depends on the amount of surplus chromosomes.
Most of them will be lost in the first few days and the
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frequency of loss decreases exponentially with time. In
mouse/mouse hybrids there is no evidence that this
chromosome loss-is anything other than random. Yet the
selective loss of a particular kind of chromosomes is
reported to happen in mouse and human hybrids, human
chromosomes being lost preferentially.
The chromosomal loss gradually stops. The
hybrids will stabilize at a chromosome number somewhere
between the diploid and tetraploid number. The. number
being different for different hybrids. The
stabilization is an asymptotic process and can never be
deemed to have reached completion. Thus, hybrids which
have been in culture for months can gradually lose
antibody secreting activity (we have confronted. this and
the incidence will be discussed later), probably due to
the development- of a non-secretor which outgrows the
secretor cells. Cloning is therefore not only important
in the early life. of a hybridoma, and may be necessary
at later stages.
If a cell loses chromosomes that are involved in
cell. replication or in some other vital metabolic
functions, it no longer contributes to the culture and
such chromosome loss is thus not important unless it
happens before the original hybrid has divided. This is
most likely to happen as the original hybrid stay at
rest for a few days before cell division starts. As
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already discussed, the chromosomes loss at that time is
greatest. Many interesting clones are being lost at
this stage and we have no way of preventing or even
decreasing it.
The most difficult problem is the loss of
chromosomes involved in antibody production or secretion
while retaining the ability to grow and replicate. This
type of cells becomes a non-secretor hybrid. The energy
taken in antibody formation are now switched to cell
growth, so it grows more rapidly than the antibody
producers. It is logical that non-secretors will
outgrow the secretors after several cell generation.
2.6.1.2 The first division of infant hybrid
Besides chromosomal instability, the hybridomas
are unstable in-other ways during the early postfusion
days. Many cells, such as unfused rnyeloma cells due to
aminopterin blockage spleen .cells due to its limited
1 i.fe span in vitro, will'-die soon after fusion. These
dead cells together with the established rapidly
dividing fibroblasts contribute much to the
complexi tus of the environment of the hybridomas. As
discussed above, the fusion products may remain dormant
for several' days in this completely new environment
before beginning to divide. They can be said to be on a
knife-edge, and can be pushed into division, or die
depending on itself and on the condition of culture.
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Yet, once they divide, this implies that they can
survive in this culture environment and thus-have great
chance to grow -up to form colonies.
2.6.2 Propagation of Hybr idoma
24 hours after fusion, .100 ul of fresh medium
with 15% FBS and double strength of HAT selective
constitutents were added to each well. As the original
culture medium had no HAT selective medium, this
addition of 100 ul double strength HAT reconstituted the
final concentration to the proper working dilution. The
addition of selective medium should be as gentle as
possible because hybrid mixtures were in a struggling
stage for survival.
At this state, besides the feeder cells, there
were 5 kinds of cells of interest, the lymphocytes and
myeloma cells which had not, been fused, myeloma cells
fused with one another, and the hybridomas formed by the
fusion of lymphocytes and myeloma cell. Under HAT
selective medium, non-fused or self-fused spleen cells
would soon die off in culture naturally myeloma cells,
whether self-fused or non-fused would not replicate due
to* aminopterin blockage only the myeloma cell fused
with spleen cell had- HGPRT from the spleen cell parent,
and therefore could utilize the salvage pathways for
replication.
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Once again, the plates were put back into the
incubator and the cells were then incubated at 370C in a
gas phase of 1.0% CO2 in air. In my experience, the
plates could be left undisturbed for at least 3 days.
During which, plates were recommended not to be taken
out for examining its clones with an inverted
microscope. As hybridomas will rest for a few days
before cell division, so any examining will definitely
view no clones, but' will only disturb the fragile
hybridomas. In addition, the 200u1 of medium should be
enough to support growth within this period.
The plates were only examined 5 days after
fusion to check for colony growth (if any) and pH of the
medium. Micro-colonies could usually be observed in
several wells (about one-tenth of total wells). If the
colour of the medium turned yellow (probably not), then
approximately half the supernatant from each well was
aspirated using a multi-channel autopipette, and then
replenished it with 100ul fresh HAT medium.
Care must be taken during this refeedinc
procedures, as clones can mostly be disturbed by this
aspirating and refeeding process, the dispersed state
was undesirable as hybridomas grew fast and best in a
form of cell clusters. In addition, this increased the
chance for non--secretors outgrowing the secreting
clones. Corollary, this would also give a misleading
53
sense of multi--hybrid clones in one well and would
increase the difficulties in cloning with a single-cell
transfer technique (Gagnon et al., 1985).
The hybrids were usually fed every 3-4 days when
the colour of the medium turned to yellow. Each time
only half of the medium was being exchanged, so that
each well contained some spent medium which was
beneficial for optimal growth of cells
2.6.3 Antibody Screening of Colonies
When colonies were macroscopic, usually, in about
10 days, medium turned yellow quickly. Supernatants
were taken for antibody screening. Experience of
handling at this stage was most important. If the
supernatants were taken early, there is a risk of
missing positive hybrids because the antibody
concentration in the supernatant was too low.
Conversely, if we waited too long, the colonies would
overgrow which might result in death of hybridomas.
Thus, it was best to test samples before the cultures
were very crowded, but to retest wells giving negative
results at a later stage. Also, it was possible that a
small amount of antibody might be produced by surviving
spleen cells, and this would give a weak positive
signal at the beginning but disappeared after a further
period of growth.
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During the withdrawal of suppernatarit for medium
exchange or for antibody screening, we used 8-channel
pipettor with sterile tips. It was normally unnecessary
to change tips throughout this procedure as antibody
carry over was minimal.
2.6.4 'Discard of any contaminated wells
Any contaminated wells or ones being suspectec
should be discarded at.once without hesitation. Do not
expect a miracle that the contaminated wells would bE
suppressed by antibiotics, as contamination only
occurs when antibiotics are completely used up or
Contamination can be easily distinguished by
examining the bottom of the wells. Bacteria-contaminated
wells will show turbidity with some precipitation
(usually white, but not definitely). Their supernatants
are turbid too. Wells contaminated with yeast will show
a large number of small size round cells with diameters
definitely smaller than hybridorna. Yeast contamination,
however, will not cause any turbidity of supernatant.
Contamination with fungi can also be easily.
distinguished with the help of a microscope. Fungi are
small rod-shaped particles, and will show branching like
a 'tree' later on.
All the contents of the contaminated wells
ineffective.
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should be discarded at once. Care should be taken not
to- spill the droplets to other wells. The wells were
then fi11ed w th 4 M HCl or 2 M NaOH. The extreme pH
can kill, the remaining contaminants.
2.6.5 Picking up of Positive Colonies
Any colonies that had been tested twice and were
found to be positive were selected out for further
expansion before cloning. Colonies should be taken out
only when half of the well was full of cells. Cells
were removed by carefully placing a sterile pasteur.
pipette in the colony and withdrawing the cells plus
medium into the pipette These cells were transferred
to a well of a 96-well plate for further expansion. To
avoid cells being in too diluted state, we only split
one well into two wails, and rarely exceeding three.
Conditioned medium (1 part filtered exhausted medium
from NS-1 culture+ 2 parts of fresh medium) were Used
for expansion. Feeder cells were usually not required
to be added to the expanded well. Wells were expanded
further when re aching corlfluency. Only when 8 wells of a
96-we-I1 tray are confluent, should we pool and transfer
them all to 2 wells of a 24-well tray. At this stage,
colonies are retested once again for their antibody
activity. If they were still positive, it was desirable
to freeze some cells down for the sake of insurance.
Even if the cells were contaminated or overgrown with
56
non-secretors later, these freezing stocks could be
taken out for further cloning.
2.6.6 Use of Hypoxanthine-thymidine (HT} medium
Cells were grown initially in HAT selective
medium for 2 weeks. All the unfused myeloma should have
died off within these 2 weeks of aminopterin blockage.
If all the HAT constituents were omitted from the medium
suddenly, the hybrids would also die out. This was
because the hypoxanthine and thymidine were used up much
faster than the aminopterin and the cells would have
neither. the de novo nor the salvage pathways for DNA
synthesis. To overcome this, cells were maintained in HT
medium for a finite period after HAT removal. This
allowed the salvage pathway to operate. After several
passage, the aminopterin concentration would have fallen
sufficiently far the de novo pathway to operate, and
hypoxanthine and thymidine could be omitted at this
stage. In my opinion, the HT medium was required for at
least two additional weeks. Some people prefer to use
HT medium in all subsequent operations, this creates no
problem but only one more step of adding substituents, to
medium.
57
2. 7 Cloning and Suboloning
Approximately 20 days after a successful
fusion, each positive hybrid was expanded to one well in
a 24-well plate. At this stage, it was essential to
clone as early as possible, as the fusion products can
still lose chromosomes. By cloning early, it was
possible to select those cells which still have the
chromosomes coding for antibody production and
secretion. Moreover, each culture well might have
multiple colonies, which might become disturbed and
mixed during the course of feeding, so it was necessary
to clone and separate them into pure populations.
2.7.1 Clones from two successful fusior
Our clones were obtained from two successful
fusion. Two positive cell lines( designated as HO1 and
H02} were obtained from the. first fusion and they were
cloned subsequently. In the second fusion, three highly
positive cell lines( designated as 2C5, 3D8 and 2B11}
were picked out for further expansion. However, one of
these cell line( 2B11) ceased to divide and was thus
lost. The remaining 2 cell lines, 2C5 and 3D8 were
also cloned.
2.7.2 Cloning by Limiting Dilution method'
Three essentially different techniques are
available for cloning:-
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(a). Cloning by technique of 'Limiting Dilution'
(b). Cloning using 'Semisolid Agar'
(c). Cloning by 'Single-Cell Transfer Technique'.
For our study, we had selected the `Limiting
Dilution method' as it required no sophisticated
equipments (Cloning using semisolid agar requires a
portable small inverted microscope that' can be put
inside the hood, whereas cloning by single-cell transfer
technique requires the use of a fluorescence-activated
cell sorter), and the cloning efficiency was relatively
high. The, principle of this technique was quite simple.
Cells were diluted to a stage where there was,
statistically, only one viable cell per well in a
culture plate. This cell then grew out to form a colony
and ultimately formed a pure antibody-producing cell
line.
2.7.3 Procedures of Cloning
Hybridomas should be in a state of good
healthiness before cloning. Autopipette was used to
gently aspirate cells up and down to disperse the
colony. Trypan blue exclusion was used to estimate the
viability of cells. If viability was less than 80%, it
was much better to delay the cloning procedure.
Each positive colony was expanded into one 96-
well plate during limiting dilution cloning. An
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appropriate volume of conditioned medium( 80% fresh
culture medium+ 20% spent myeloma culture medium) was
added to 0.1 ml cells to bring the cell density down to
300 cells/ml. Two 10 fold dilutions were made to yield
a concentration of 30 cells/ml and 3 cells/ml
respectively. As each well contained 0.1 ml, a cell
distribution of 0.3 cell,/well, 3 cells /well and
30 cells/well was obtained.
Of the 96 wells, 48 wells were filled with 0.3
cell/well 24 wells with 3 cells/well and the
remaining 24 wells with 30 cells/well. The plates were
incubated until colonies could be observed.
2.7.4 Suboloning
In the cloning of the two cell lines from
the first fusion, several wells had colony
proliferation. Two, of the most strongly positive clones
were selected from wells of the lowest cell
concentration.
Statistically, if cells are grown in small
numbers, the fraction of wells with growth follows the
Poisson distribution
where f (O) is the fraction of wells with no growth, and
A is the average number of clones per well. If A= 1,
f (O)= 0.37, that means, to obtain a reasonable
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probability that wells which show growth contain single
clones, more than 37% of wells should have no growth.
In our case, less than ten wells had detectable colony
growth, the colony might be assumed to contain single
clone, that is, derived from one mother cell. To
guarantee monoclonality, recloning of the two most
positive clones from each plate was carried out.
Finally, two subclones had been derived from each of
the original cell line in the first fusion experiment.
Altogether four subclones were produced, H02a1 and H02b1
from one cloned cell line (H02a), HOlal and HOlbi from
the other (HOla).
Similarly, cloning and suboloning had been
performed for the two cell lines derived from the second
fusion experiment, three subolones, aC10, aC12 and bFi1
were generated from the same clone which was ultimately
derived from the 2C5 cell line. Five clones were
obtained from the other original cell line 3D8. Further
subclonirig of these would be carried out in the future.
Seven hybridomas secreting monoclonal antibodies
to ADH had been produced so far for this work. Clone
H02a1 was soon found to lose its antibody-secreting
activity, probably due to the overgrowth of newly
derived non-secreting mutant. Only four out of the
remaining six clones were further expanded and their
corresponding monoclonal antibodies had been purified
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and- characterised (Fig. 2. 4), the results of this work
will be presented in this thesis.
2.7.5 Freezing and Thawing of hybridomas
Cells from healthy mid-log phase were counted
and centrifugated. The cell .pellet was resuspended in
cold freezing medium at a cell concentration of
approximately 5 x 10 6 cells/ml. 1 ml aliquots of cell
suspensions were dispersed into an ampule and was put to
the liquid nitrogen container for gradual freezing and
storage( about 4 hours were enough to cool down the
cells to -170°C).
Freezing medium consisted of 70% RPMI medium,
20% FBS and 10% DMSO. They could be prepared in advance
and stored at 4°C until use.
For reactivation of frozen cells, a vial of cell
was taken out of the liquid nitrogen container. The
cells were thawed quickly by placing them in a 37°C
water bath with constant agitation. As soon as they
were thawed, cells were taken out and transferred to a
sterile centrifuge tube. Cold culture medium
supplemented with 10% FBS was added gradually to dilute
out the freezing medium. Cells were spun down gently
and resuspended in an appropriate volume of complete
medium (RPMI+ 10% FBS). Cell viability was determined
by trypan blue dye method. If the viability was low
(<70% cells were resupended in a minimal volume of
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Fig. 2.4 Chart showing the derivation of hybridoma
subclones. Two cell lines, HO1 and H02 were produced
from the first fusion. On further subcloning, each of
them produced two subclones. Eventually, H02a1 finally
ceased to produce specific antibody and was lost. In
the second fusion experiment, three positive cell lines,
2C5, 3D8 and 2B11, were selected out. Cell line 2B11
was lost, 3D8 was still being cloned and 2C5 produced
three clones. One of theca, A10, finally produced three
subclones, bFl1, aC12 and aCIO. The four subclones,
HOlal, Holbl, H02b1 and 2C5 (marked with an asterisk)
were taken out for exians ion and rah rar tpri mat i nn





















culture medium (20% spent culture medium+ 60% fresh
medium+ 20% FBS) at a cell concentration of about
7 x 10 cells/ml and incubated bated at 37 0 C. Cells were
inspected after 12 hours and then adjusted to the
desired density in normal culture medium and allowed to
grow. If the viability of the thawn cells was high
( 90%), they were suspended at about 3 x 10 5 cells/ml
in normal medium and cultured.
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CHAPTER 3 PURIFICATION OF MONOCLONAL ANTIBODIES
TO HUMAN LIVER ALCOHOL DEHYDROGENASE
Typical antibody concentrations in serum or
ascites of hybridoma-bearing mice range from 2-20 mg/ml,
and thus represent a significant fraction of all protein
present. However, normal polyclonal antibodies from
ascites-bearing mice may diffuse out from circulation
into the ascites fluid. Thus, it will interfere with the
antibody's specificity. In contrast, the antibody
levels in culture supernatants of hybridomas are of
the order of 2-10 ug/ml. Hence, the yield of
purification of antibodies from ascitic fluid will. be
much higher than that from culture supernatant.
As the strategy for antibody purification is
determined by the antibody class and subclass, so the
first step is to identify the class and subclass of the
monoclonal antibodies that we are dealing with.
3.1 Determination of Antibody Class and, Subclass
Several techniques may be employed to determine
the antibody class and subclass. These include
radioimmunoassay, enzyme-linked immunosorbent assay and
direct immunofluorescene assay. In the present study,
the Ouchterlony immunodiffusion technique was used
because it offers the simplest mean. to determine
antibody class and subclass. The mouse monoclonal typing
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kit was purchased from S erotec, U.K].. It contained a
set of thin agarose gel diffusion plates with holes in
the form of rosette and affinity purified antisera
against IgG1, IgG2a, IgG2b, IgG3, IgA and IgM.
Hybridoma culture supernatant is employed as the
testing sample because of its concentration,
approximately 3 ug/ml, falls into the immunoglobulin
range of the kit, 1-20 ug/ml. This test was not used
for antisera or ascitic fluid collected from mice primed
with hybridoma because antibody obtained from these
sources. may cause ambiguous results due to the
concurrent presence of normal immunoglobulin of
different classes from the primed mice.
3. 1. 1 Procedures
Approximately 75 ul of the test culture
supernatant spipetted into the large central hole of
one of the rosettes. 10 ul of each of the six antisera
against IgG1, IgG2a, IgG2b, IgG3, IgA and IgM were then
pipetted, in a documented fashion, into each of the
outer six wells. Care was taken to avoid overflooding
and spilling. The plate was then tightly closed and
stored flat at room temperature overnight. Afterwards
the immunoprecipitin lines relevant to the
immunoglobulin specificity will be visible.
In order to preserve the lines, we usually
66
waited for at least 4B hours, until the white precipitin
lines were distinctively visible.. The plate was then
immersed into. PBS for 2 days to remove unprec ip itated
proteins. After the plate was blotted dried, it was
then immersed into a 0.2% Fast Green solution until the
precipitin lines were fully stained. The gel was then
transferred to a 7% acetic acid solution to de stain
until the background was clear. Acid was removed by
immersion in water. The gel was-then mounted on a piece
of plastic wrap. Water inside the gel would then
diffuse out in about 2 days. The gel would dry out as a
thin layer and it could be pre served for a long time.
3.1.2 Result
The antibodies derived from their corresponding
labelled HO1al. HOibl, bF11 and 3D8 respectively all
formed precipitin lines with anti-1gM. While the
antibody, H02b1, was formed precipitin line with anti-
?g01( Fig. 3.1}. None of the monoclonal antibody
tested showed cross reactivity with more than one type
of anti-immunolobulins( Table 3.1).
Fig. 3.1 Double immunodiffusion assay in determining
antibody class subclass. The central wells
were filled with culture supernatants of
hybridomas HOlal, HOlbl, H02bl, bFll 3D8
respectively. The peripheral six wells were
filled with the corresponding' anti-class
antibody[ 1= anti-IgG3, 2= anti-IgG2b,
3= anti-IgG2a, 4= anti-IgGl, 5= anti-IgA
6= anti-IgM].
68
Table 3. 1 Class Subclass of-antibodies derived from
their corresponding hybridomas.
Antibodies from








As the four monoclonal antibodies raised were
either IgM or IgGv two purification schemes were
employed. It was advantageous to combine several
fractionation methods as each step would remove
different grades of undesirable'contaminants. Thus very
high sample purity might be obtained. On the other hand,
the degree of protein denaturation and yield would also
be affected by the number of manipulations required in
the purification scheme. Thus, to optimize the
isolation condition, a balance procedure not involving
too many steps has to be worked out.
Our purification scheme was quite simple and the
immunoglobulin samples obtained could only be regarded
as partially pure. The purification of IgG (H02bl)
would be discussed first, then followed by IgM (HOlal,
HOlbl, bFll).
3.2.1 Procedures for purification of IgG
monoclonal antibody against APR (H02bl)
Step 1: Collection of ascitic fluid
Each BALBc mouse was injected intraperitoneally
(i.p.) with 0.5 ml pristane. Ten days later, 5-10 x 10
histoeompatible hybrid cells (H02bl) were also injected
i.p. into each mouse and this resulted in tumour
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formation in the peritoneal cavity after 3-4 weeks.
Ascitic. fluids were then collected from H02b1
innoculated mice by using a 18 gauze needle to pierce
the swollen abdomen. Ascitic fluid would drip out
drop by drop and massage of the swollen abdomen was
found to increase the rate of extrusion. Approximately
7-12 ml of ascitic fluid could be, collected in the first
time. Mouse was then left for about 2 days and ascitic
fluid was collected again. This time the volume was
usually lesser than before. Ascitic fluid could be taken
from one mouse for about three to four times by this
method. The ascitic fluid taken out each time could be
stored at -20 0C until enough volume was saved for
purification. Meanwhile, blood could also be taken out
from the mouse's tail or from the eyes.
Step 2: Clarification of ascitic fluid
About 25 ml of frozen ascitic fluid containing
25-25Q mg of monoclonal .antibody were processed. each
time. This volume was chosen for ease of handling.
The thawed ascitic fluid was filtered by suction through
cheesecloth twice to remove large aggregates of lipid
and cellular debris. The filtrate was then collected
and taken for centrifugation at 10 000xg for 30 minutes
to remove small particulate matter.
Step 3: Ammonium sulpnate precipitation
The supernatant from the centrifugation step was
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sequentially precipitated with 45% ammonium sulfate.
Saturated ammonium sulfate solution was prepared at
least one day before by adding 850 gm of solid
ammonium sulfate into 1 litre of 700C double distilled
water. The solution was stirred for 2 hours and its pH
was adjusted to 7. 4 and then left at 40 C overnight.
Next day, when some undissolved solid was seen at the
bottom of the vessel, the solution was deemed to have
reached saturation. pH could be adjusted once again.
The solution should always be kept at 4 C as the
percentage of saturation changes slightly with
temperature.
The supernatant from the centrifugation step was
diluted three fold with double distilled water and was
placed in a beaker surrounded by an ice bath. The whole
set up was placed on a magnetic stirrer. Stirring
should be slow as frothing denatures protein. Cold
saturated ammonium sulfate solution was added dropwise,
allowing each drop to disperse before the next was added.
When the concentration had reached 35% saturation, the
solution would begin to turn milky. When 45% saturation
was reached, the suspension should be stirred for 15-30
minutes, and then centrifugated at 10, 000xg for
30 minutes. The supernatant contained a small amount of
fine lipoprotein on its top and it should be discarded
with the turbid supernatant. The precipitate was then
suspended in PBS in one-fifth of the original volume of
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diluted ascites, and was reprecipitated with 45%'
ammonium sulfate. The precipitate was then suspended in
PBS in one-tenth of its original volume.
Ammonium ions would interfere with many
subsequent procedures, so the high salt was removed by
extensive dialysis against 1 litre of 0.01 M phosphate
buffer, pH 7.4. The dialysis fluid should be changed
several times at intervals of a few hours.
The precipitation of immunoglobulin by ammonium
sulfate was based on the observation that they were
precipitated by lower concentrations of ammonium sulfate
than most other serum proteins. The whole process was
gentle, effective and simple to perform. Though it was
not possible to purify immunoglobul iris to homogeneity,
it provided a substantial enrichment and reduced the
protein load on subsequent steps.
There are few technical points to be noted in
the whole process. It was preferable to add ammonium
sulphate slowly in the form of a saturated aqueous
solution, rather than as_solid crystals. High local
concentrations of ammonium sulphate caused unwanted
precipitation of proteins such as albumin. and thus
decreased the degree of purification. The lipoprotein
in the form of small particle at the 'top of supernatant
was found to adhere to the side of the centrifuge tube
and should be wiped away with tissue paper.
Step 4 DEAE—cellulose chromatography
Among the ascitic proteins, IgG is the least
negatively charged protein and it is weakly bound to
anion exchanger. So DEAE-cellulose column was employed
to purify it.
The sample was loaded on a DEAE-cellulose column
which was pre-equilibrated with 0.01 M phosphate buffer,
pH 7.4. The column had a good capacity of about 30 mg
protein per ml packed volume. The protein content of
the IgG enriched dialysate was estimated by absorption
at 280 nm( Imgml of protein gives an absorbance of
1.4 in 280 nm) before loading onto the column.
After loading, the column was washed with 0.01 M
phosphate buffer. Optical density was monitored until
it reached a background value( 0.01). The column was
then eluted with a buffer of higher ionic strength
( 0.01 M phosphate buffer+ 50 mM NaCl). A sharp peak
of IgG would then come out.
The selection of 50 mM NaCl for elution of IgG
was based on the scheme for 'Purification of
Immunoglobulin by Parharc, 1981; Parharn and Brodsky,
1981. In the purification of mouse monoclonal IgGl by
DEAE-cellulose chromatography, they used a gradient of
0-100 mM NaCl. From their work, we could see that IgG
was eluted at 50 mM NaCl. Therefore, we had chosen this
ionic strength to elute our IgG sample.
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Stop 5: Lyophilization of IgG
The IgG samples were dialyzed extensively with
0.01 M ammonium acetate, pH 7.4. The dialyzed samples
were then lyophilized to remove the solvent together
with the salt. As we know, salt will affect binding of
immunog l obul in, but more importantly, the salt would
also have significant influence on the enzyme kinetics
of ADH.
Step 6: Miscellaneous Steps
The fractions obtained after each purification
step was saved and assayed for its protein content and
IgG content. Their purity was also monitored by SDS gel
electrophoresis.
Protein contents of -samples were assayed by
serially diluting the samples in volumes of 0. 2. ml.
2 ml of alkaline-copper sulfate solution were added and
mixed with it. This reagent was prepared immediately
before use by combining 1 ml 2% (w/v) CuSO4• 5H20 with
1 ml 4% (w/v) potassium tartrate and diluting to 50 ml
with 3% (w/v) Na2CO3 in 0.1 M' NaOH. After 10 minutes,
0.2 ml of 1 N Folin and. Ciocalteu Phenol Reagent was
added to each sample with immediate and vigorous mixing.
The absorbance at 750 nm was read after allowing the
colour to develop over a 30 minute period at room
temperature. Protein standards in concentrations
ranging between 25 and 200 ug were prepared
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simultaneously using an aqueous solution of crystallized
bovine serum albumin (Lowry et al., 1951).
Slab gel SDS-polyacrylamide gel electrophoresis
was used to separate different molecular weight protein
in each fraction. Discontinuous SDS-PAGE was performed
under denaturing condition. As',the molecular weight of
IgG was 140, 000, so a 5% separating gel was suitable.
The 5% separating gel' was freshly prepared
before use.. it consisted of 6.6 ml Solution A (30%
acrylamide, 0.8% BIS), 10 ml of Solution B (1.5 M Tris,
pH 8.8)$ 0.4 ml of Solution C (10% SDS), 20 ul of TEMED
and 40 mg of ammonium per sulfate, water was added to
bring up the total volume to 40m1. They were poured into
a slot of 2 mm thick formed by two glasses. After
polymerization, a rectangular separating gel was thus
obtained. Later, a 3% spacer gel was added to the top
of the separating gel, it was also freshly prepared and
consisted of 1 ml Solution A, 0.1 ml of Solution C,
2.5 ml of Solution D (0.5 M Tris, pH 6. 8), 5 ul of TEMED
and 10 mg of ammonium persulfate.- Water was added to
bring the final volume to 10 ml. A comb was. put at the
top of the spacer gel in order to form the slots for
sample application later. 10ul of samples diluted with
an equal volume of sample buffer (1.25 ml of Solution D,
1 ml of Solution C. 0.1 ml of 2-mercaptoethanol,
1 ml glyerol, 0.2 ml of 0.1% bromophenol blue and
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1.45 ml of water) were boiled for 2 minutes. 15 ul of
sample mixtures were then applied to the sample slots.
Tris-Glycine-SDS buffer( 0.3% Tris, 0.144% glycine and
0.1% SDS) was used as the electrophoresis buffer.
Samples were run at- a constant voltage of 200 V.
The run was stopped after the tracking dye had reached
the end of the gel. The gel was then stained( 0.25%
Coomassie blue, 45.4% (v/v) absolute methanol, 9.2%
(v/v) glacial acetic acid) for 3 hours and then
destined overnight (50% methanol, 7.5% acetic acid).
3.2.2 Experimental results of purification of IgG (H02b1)
3.2.2.a DEAE-cellulose chromatography of IgG after
precipitation with 45% ammonium sulfate
Fig. 3.2 was a chromatogram obtained when the
IgG-rich (H02b1), ascitic dialysate was passed through a
DEAE-cellulose column. The column was first washed
with 0.01 M phosphate buffer, pH 7.4 to remove all the
unabsorbed materials. The eluent was monitored by
absorption at 280 nm until it dropped to 0.01. As
indicated in the chromatogram, two peaks, named
`Peak A' and `Peak B, were obtained. `Peak A' was
colourless and `Peak B' was pale orange.
The eluting buffer was then changed to a higher
ionic strength (0.01 M phosphate buffer with 50 mM NaCl).
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Fig. 3.2 DEAE-cellulose chromatogram of purification
of monoclonal antibody H02bl.. After loading with
samples, the column was run with Buffer A( 0.05 M
phosphate buffer, pH 7.4) at a flow rate of 0.4 ml'min..
Two protein peaks were obtained, named Peak A'
( of fraction 1-4) and Peak B'( of fraction 30-34).
Then Buffer B( 0.05 M phosphate buffer+ 50 mM NaCi)
was applied, 1 Peak C' (of fraction 54-63) was
collected. Later when the eluting buffer was 1 Buffer C7
( 0.05 M phosphate buffer+ 1 M NaCl), Peak D 7( of
fraction 78—06~) was collected. The four 'Peak7
fractions were 'pooled and 100 ul of them were assayed
with ELISA binding curve of H02bl( shown in Fig. 4.5).
The shaded area represented the amount of specific anti-
ADH antibody in such pooled peaks. The amount of
specific antibody in Peak A 7 and 1 Peak B 7 was less
than 1 ug 100 ul eluent and was. not shown in the
figure.
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eluted( `Peak C'). The Q.D. of this peak was 11.2.
When the absorbance reached the baseline level again,
the eluting buffer was changed to 0.01 M phosphate
buffer+. 1 M NaCl. All the strongly bound proteins were
removed by this step( `Peak D').
Fractions correponding to each of the four peaks
were pooled and 100 ul of the pool samples were taken to
assay for their antibody titer according to a ELISA
antibody titration curve described later in Section 4.2
of Chapter 4.
High level of antibody was detected in `Peak C'
fraction, there was 97.36 ug of anti-ADH IgG antibody/
100 ul of eluent (the amount of specific antibody was
traced from H02b1 ELISA binding curve. shown in Fig. 4. 5).
The IgG content in `Peak D' was also high( 24.15 ug of
specific antibody/ 100 ul of eluent?. Both` Peak A
and` Peak B' showed very low activity, being less
than 1 ug of specific antibody/ 100 ul of eluent.
3. 2. 2. b Electrophoresis of 4 eluent peaks
The above 4 peaks were electrophoresisea in a
7% SDS gel to determine purity and molecular weights.
Ascitic fractions and purified standard IgG were also
included for comparison. The molecular weight of the
major band in Peak C' corresponded to the same
molecualr weight as IgG( Fig. 3.3). Thus most of the







Fig. 3.3 SDS-PAGE gel electrophoresis of four pooled
peak fractions collected after DEAE-cellulose
chromatography of H02b1 ascitic fluid. Standard protein
markers and standard IgG were included here for
comparison. A distinct band was shown in `Peak C'
fraction in a position corresponding to that of standard
IgG. So the majority of protein in `Peak C' fraction
was IgG. Whereas a smaller band in the same position as
that of IgG was observed in `Peak D' fraction, and
lesser amount of proteins was seen in both `Peak A' and
`Peak B' fractions. It was believed that the proteins
present in these two peaks were small molecular weight
proteins, and were run out of the gel location and thus
not seen here. A stronger-protein band corresponding to
that of IgG was seen in the ascitic fluid fractions.
materials isolated in this fraction should be IgG. At
the same time, a relatively weak band corresponding to
IgG was also seen in 'Peak D'. This probably accounts
for the low percentage of IgG recovery.
3.2.2.c Screening of 'Peak CJ with densitometer
The content of actual specific IgG in 'Peak C'
was determined using a densitometer. As indicated in
Fig. 3.2, 'Peak C' contained materials other than IgG.
In order to determine its specific IgG content, the area
of the IgG peak over that of the total protein was
determined. By measuring the total protein content of
'Peak C', we could then calculate the actual amount of
specific IgG in 'Peak C'. According to the densitometer
tracing, the percentage of specific IgG in 'Peak C' was
over 90%( Fig. 3.4).
3.2.2.d Purification fold of specific anti-ADH IgG( H02bl)
The purified H02bl( anti-ADH IgG) antibody
after each purification step was assayed for their
specific antibody content using the ELISA binding assay
described in Fig. 4.5. The specific antibody content in
0.1 ul samples was determined from the binding curve of
H02bl. Multiplying this value with the volume of
amp 165 gave the amount of specific anti ADH Igu
antibody. The amount of specific antibody at each
purification step over that of the total specific
Peak C screening Baseline screening
Fig. 3.4 Density screening of %Feak C fraction. The
Peak C fraction was previously collected from DEAE-
eellulcse chromatography after application of Buffer B,
and was then taken for SDS-PAGE electrophoretic run( as
shown in Fig. 3.2 and Fig. 3.3). It was screened with
a densitometer- From the gel,. the tracking dye had a
long tail, so the base line could not be those shown in
the right graph. An arbitary base-line was drawn, as
shown in the left graph..
antibody in the ascitic fluid( before purification)
would give an estimate on the percentage of recovery
after each purification step.
As shown in Table 3.2, 28.73% of the original
specific antibody was recovered after ammonium sulfate
precipitation. Most of the IgG was lost in this step
since during the dialysis, a pale brown precipitate was
found and it may be the IgG that we are interested. At
this particular stage, the concentration of IgG was very
high, about 280 mgml, and since its solubility may
decrease in low ionic strength, increasing time of
dialysis may induce an unusally high precipitation.
In order to determine the enrichment of specific
antibody after each purification steps, the protein
content of samples after each purification step was
firstly determined by Folin Lowry method. The amount of
total specific antibody over that of total protein
content would give the 'yield' of the specific antibody
at each stage.
Comparing the yield after each purification step
with that of the ascitic fluid, the fold of enrichment
can be calculated. According to this, the ammonium
sulfate precipitation step produced a 1.8 fold of
enrichment and DEAE-cellulose chromatography produced a
9.1 fold.

































3 0.936 0.1711 ug 3.40% 3.488 490.57 9.137
Footnotes to Table 3.2. Purification of monoclonal
antibodies H02bl. Purification was performed in two
steps, ammonium sulfate precipitation and DEAE-cellulose
chromatography. 22 ml ascitic fluid obtained from mice
injected with the H02bl hybridoma were precipitated with
45% ammonium sulfate and then dialysed extensively
against 0.01 M phosphate buffer, pH 7.4. The sample was
then loaded onto a DEAE-cellulose column of 1.5 x 25 cm.
The 'Peak C' fractions were collected and pooled. After
dialysed with 0.01 M ammonium acetate, pH 7.4, it was
lyophilized. The powder was finally suspended in 3 ml
of PBS. Small amount of samples from each step of
purification was assayed for protein and specific
antibody content (by ELISA binding' curve of H02bl as
shown in Fig. 4.5). Multiplication of sample volume
with specific antibody concentration gives the total
amount of specific antibody at each step. By comparing
the total amount of specific antibody at each step with
that of the ascitic fluid, the percentage of recovery
can be calculated. The yield of specific antibody
after each step of purification .was determined by
dividing the amount of specific antibody per 0.1 ul
volume at each step with the protein content.
Enrichment of specific antibody in each step can be
obtained by dividing the yield after each step of
purification with that of ascitic fluid.
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3.2.3 Procedures for purification of IgM monoclonal
antibodies against ADH( HOlal, HOlbl and bFll}
purification
The purification of IgM was not as easy as that
of IgG. As IgM normally exists as a pentamer of the
basic immunoglobulin unit, covalently bonded together
through their Fc regions by a small polypeptide chain
called `J chain'. Because of its large size (molecular
weight 900, 000), gel filtration is an important step in
its purification.
Step 1 2:
Tne steps or coi.lectlon ana clarlrication o:
ascitic fluid' for IgM are exactly identical to those o:
TgG
Step 3: Ammonium sulphate precipitation
Most IgM molecules are insoluble at low ionic
strength and so an euglobulin precipitation step (i. e.
precipitation at low ionic'strength) was suggested to be
a useful preliminary procedure (Garvey- pt al., 1977).
However, euglobulin precipitation caused denaturation.
Additionally, not all. IgM proteins were euglobul ins.
Hence, we still prefered to use ammonium sulfate
precipitation
Step 4: Sephadex G200 spun column
Miniature gel chromatography spun columns were
used here to separate IgM from ascitic samples by
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exploiting the molecular weight and size differences
between IgM and other serum antibodies. Sephadex G200
gels were chosen to exclude proteins with molecular
weights greater than 200, 000. IgM, 900,000 MW, were
excluded while other proteins such as albumin, about
70,000, were retained in the column.
Sephadex G200 was hydrated overnight at room
temperature in PBS. Disposable 2.5 ml syringe barrels
which had been plugged at the needle end with glass wool
were used as columns. Swollen gels were packed to a
height of 3 cm. The gel-filled barrels were then
centrifuged in a swingout bucket rotor at 200 xg for
30 minutes at room temperature. Column height was
reduced by approximately 1 cm after this treatment.
0.5 ml samples were added to the columns.
Ascitic dialysate was diluted three fold in PBS before
application. Centrifugation of the sample-loaded
columns accomplished the separation, in one step, by
eluting a void volume equal to the sample volume from
each column into a holding tube. The eluent after
centrifugation was pooled.
3.2.4 Experimental results of purification
of IgNI( HOlal, H01bl and bFll}
The three eluted IgM samples were assayeri tor
their antibody and total protein content. The
results of purification were shown in Table 3.3,
Table 3.4 and Table 3.5 respectively.
The recovery of specific anti~ADH IgM after
ammonium sulfate precipitation in samples of HOlal and
HOlbl were 31.56% and 29.68% respectively. It is
clear that more than two-th'irds of the specific
antibodies were lost. 12.69% and 11.63% of the total
amount of specific IgM in the samples were recovered
after spun column separation. Thus, about 60% of
specific IgM was lost in this step.
The recovery of specific IgM of bFll aftei
ammonium sulfate precipitation was the highest (37.81%).
Moreover, 17.64% of specific IgM of bFll were recovered
after spun column separation, indicating that less thar
60% of IgM vas lost in this step.
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Footnotes to Table 3.3. Purification of monoclonal
antibodies HOlal. Purification was performed in two
steps, ammonium sulfate precipitation and Sephadex G200
spun column purification. 26 ml ascitic fluid obtained
from mice injected with the HOlal hybridoma were
precipitated with 40% ammonium sulfate and then dialysed
extensively against 0.01 M phosphate buffer, pH 7.4.
100 ul of dialysed samples was added to each pre-packed
Sephadex column. After centrifugation, the eluted
samples were collected and pooled, it was lyophilized.
The powder was finally suspended in 2 ml of PBS. Small
amount of samples from each step of purification was
assayed for protein and specific antibody content (by
ELISA binding curve of HOlal as shown in Fig. 4.5).
Multiplication of sample volume with specific antibody
concentration gives the total amount of specific
antibody at each step. By comparing the total amount of
specific antibody at each step with that of the ascitic
fluid, the percentage of recovery can be calculated.
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2 1.848 11.68% 5.77
Footnote referred to Table 3.3
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2 1.171 17.64% 8.92
Footnote referred to Table 3.3
CHAPTER 4 CHARACTERIZATION OF MONOCLONAL ANTIBODIES
TO HUMAN LIVER ALCOHOL DEHYDROGENASE
Four stable hybridoma clones against human liver
alcohol dehydrogenase were established. The monoclonal
antibodies (HOlal, HOlbl, H02bl and bFll) secreted by
them had been purified in large quantities. Their
specific properties on enzyme activity and kinetics are
the subject of the following study.
4.1 Inhibition of enzyme activity on crude extract of ADH
4.1.1 Procedures of assay
ADH catalyses the oxidation of ethanol by NAD




Enzyme activity is monitored by the rate of
production of NADH. This was essentially carried out at
20°C by monitoring the rate of NAD+ conversion to NADH
at 340 nm in a Varian Cary 210 Spectrophotometer.
Different concentrations of the purified
antibodies were incubated with ADH beforehand at
different conditions. The standard reaction mixtures
( 1 ml final volume) contained 5 ul crude ADH( enzyme
activity is 2.37 Umg protein), 40 ul of antibody or
glycine buffer( blank), 30 ul of b% NAD, 20 ul uf
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2 M EtOH and 905 ul of 0.1 M glycirie buffer, pH 9.0.
The reaction was'started when all the constituents were
mixed.
One unit (U) of ADH activity is defined as the
amount of enzyme required to produce lumol of NADH/min.
at 200C. As the molar absorptivity is 6.22 mmol -1 cm -1
therefore, the ADH activity can be calculated as follow:
0. D. /min. X dilution factor of enzyme
Activity in assay mixture
(U/mg)
6.22 X conc. of ADH enzyme
4.1.2 Experimental results on the inhibition of enzyme activity
by monoclonal antibodies
The four antibodies were pre-incubated with ADH
at four different conditions 8 hours at 4°C, 8 hours at
20 °C, 2 hours at 4°C and 2 hours at 37°C.
Since incubation for 2 hours at. 37 0C resulted in
no enzyme activity irrespective of the presence of the
antibody, it is apparent that this incubation
temperature may have deleterious effects on enzyme
activity.
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4. 1. 2. a Inhibition of enzyme activity by antibody H02b1
Antibody H02b1 caused a concentration-dependent
inhibition of ADH activity at all of the three
incubation conditions tested. From Fig. 4.1, the
inhibition of enzyme activity was positively related to
the amount of antibody in the incubation medium. At
antibody level lower than 0.015 ug, there was only a
slight inhibition of ADH activity under the conditions
tested. However, as the level of antibody was increased
to 30 ug, a rapid inhibition of enzyme activity was
obtained. This inhibition was apparently time and
temperature dependent since longer incubation at higher
temperature would bring about the highest 'Level of
inhibition.
4.1.2.b Inhibition of enzyme activity by monoclonal antibodies
HOlal, HOlbi and bFll
These three antibodies showed the same pattern
of inhibition of enzyme activity as H02b1. The
inhibition was again dependent on the amount of
} .antibodies added( Fig. 4.2 Fig. 4.3 and Fig. 4.4
4.2 ELISA binding
The binding of• the four purified monoclonal
antibodies to immobilized ADH was examined by the ELISA
technique used for antibody screening as described in
Chapter 2, section 2.2.
Amount of Antibody (ug)
Fig. 4.1 Inhibition of enzyme 'activity of ADH by
antibody H02bl. Crude extract of ADH was pre-incubated
with different amounts( 0.15 ug, 1.5 ug, 15 ug, 30 ug]
of specific antibodies at three different incubation
conditions[ 8 hours at 4°C 8 hours at 20°C
2 hours at 4°C and was assayed for enzyme
activity as described in experimental procedures.
Control activity( 100%) was obtained when the ADH
enzyme was pre-incubated with glycine buffer only, and
its value was 23.732 Umg protein after 8 hours at 4°C;
18.537 Umg protein after 8 hours at 20°C and
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Fig. 4.2 Inhibition of enzyme' activity of ADH by
antibody HOlal. Crude extract of ADH was pre-incubated
with different amounts( 0.2 ug, 2 ug, 20 ug and 40 ug)
of antibody HOlal at three different incubation
conditions[ 8 hours at 4°C 8 hours at 20°C
2 hours at 4°C and was assayed for enzyme
activity as described in experimental procedures.
Control activity( 100%) was obtained when the ADH
enzyme was pre-incubated with glycine buffer only, and
its value was 26. 197 Urng protein after 8 hours at 4°C;
22.683 U'mg protein after 8 hours at 20°C and
25.863 Umg protein after 2 hours at 4°C.
100806040200






Fig. 4.3 Inhibition of enzyme activity of ADH by
antibody HOlbl. Crude extract of ADH was pre-incubated
with different amounts( 0.5 ug, 5 ug, 10 ug and 50 ug)
of antibody HOlbl at three different incubation
conditions[ 8 hours at 4°C 8 hours at 20°C
2 hours at 4°C and was assayed for its enzyme
activity as described in experimental procedures.
Control activity( 100%) was obtained when the ADH
enzyme was pre-incubated with glycine buffer only, and
its value was 26.197 Umg protein after 8 hours at 4°C;
22.683 Umg protein after 8 hours at 20°C and
25.863 Umg protein after 2 hours at 4°C.
100806040200






Fig. 4.4 Inhibition of enzyme'activity of ADH by
antibody bFll. Crude extract of ADH was pre-incubated
with different amounts( 0.4 ug, 4 ug, 20 ug and 40 ug)
of antibody bFll at three different incubation conditions
8 hours at 4°C 8 hours at 20°C 2 hours at
4°C and was assayed for its enzyme activity as
described in experimental procedures. Control activity
( 100%) was obtained when the ADH enzyme was pre-
incubated with glycine buffer only, and its value was
18.236 Umg protein after 8 hours at 4°C; 16.193 Umg
protein after 8 hours at 20°C and 24.179 Umg protein
after 2 hours at 4°C.
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4.2.1 Experimental results of specific binding
As indicated in Fig. 4.5, the binding of all of
the four antibodies to ADH coated plates was
proportional to the log of concentration of the
antibodies. There was no indication of saturation even
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Fig. 4.5 Monoclonal antibody titration curves by ELISA.
96 well immunoassay plates were first precoated with
3 ug crude ADH enzyme at 4°C overnight. After washing
unbound enzyme and saturation of the wells with excess
BSA, the wells were pre-incubated with varying amounts
( 0-80 ug) of monoclonal antibodies[ H02b1(*);
HOlal (); HOlbl(); bFll()]. Bound antibodies
were detected by ELISA technique with goat anti-mouse
immunoglobulins-peroxidase conjugate as described in
details in Chapter 2, section 2.2.3.
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CHAPTER 5 CONCLUSION AND DISCUSSION
5.1 Review of the hybridoma technolo9v
The last ten years have witnessed the birth and
development of modern biotechnology, particularly
recombinant DNA technology and hybridoma technology.
The latter one is indeed a monumental achievement of
Kohler and Milstein (1975) who showed that somatic cell
hybridization could be used to generate a continuous
hybridoma cell line capable of producing monoclonal
antibody. Hybridoma technology has fulfilled one of the
major goals that immunologists have been trying to
achieve for years: the routine production of large
amounts of homogeneous antibody against a wide range of
antigens. Moreover, hybridoma technology can also be
applied to investigate the genetic, biochemical, and
molecular basis of immune response.
The success of Kohler and Milstein was due to
their ingenious culmination of many seemingly unrelated
discoveries by other workers. Of particular importance
was the proof of the clonal selection theory (Nos-sal and
Lederberg, 1958) the development of cell fusion
techniques (Okada, 1962 Littlefield, 1964), the
artificial induction of plasmacytomas (Potter and Boyce,
1962), and their adaptation to tissue culture (Horibata
and Harris, 1970). Finally, the demonstration that it
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was Possible to fuse two different tumour plasma cell
lines with the retention of antibody products (Cotton
and Milstein, 1973) paved the way for the breakthrough.
With the development of hybridoma techniques, it
is theoretically possible to produce unlimited
quantities of exquisitely specific antibodies against
virtually any molecule, regardless, of the purity of the
immunizing antigen. The fine specificity, degree of
cross-reaction, affinity, and physical properties
( antibodies class/subclass) of the antibodies may be
selected to suit individual needs. It would be wrong to
think that monoclonal antibodies will completely replace
conventional serology. As the whole process of
production and of purification of monoclonal antibodies
involves a great deal of work and a high level of
commitment, so polyclonal antibodies may be preferred
when the antigen to be recognized is denatured or
altered in some other way.
5.2 An overview on the production of monoclonal antibodies
to hman 1ivpr alcohol dehvdr. ogenase
BALB/c mice were immunized with adjuvant-
emulsified antigen( crude- ADH enzyme) twice. The
animal showing strong. circulating antibody titer was
given a last booster. Four days later, the mouse was
killed and spleen was removed aseptically and
mechanically disaggregated. Vi able single cells were
counted. Spleen cells were then mixed with NS-1 myeloma
cells in the ratio of 10: 1. 50% of polyethylene
glycol was added to activate the cell surface to promote
fusion.
Following cell fusion, there will be a mixture
of unfused spleen cells, unfused myeloma cells, spleen X
spleen hybrids, myeloma X myeloma hybrids together with
the desired spleen X myeloma hybridomas. The mixed cell
population was then cultured in HAT selection medium,
which block the cells' main nucleic acid synthetic
pathway. Normal spleen cells and spleen X spleen
hybrids have a limited lifespan in vitro and will die
out naturally after several days in culture. Unfused
myeloma cells and myeloma X myeloma hybrids are
eliminated by aminopterin blockage. Hybridomas,
however, survived by obtaining the HGPRT genome from the
spleen mother cell. HGPRT allowed them to utilize
hypoxanthine to synthesize nucleic acids.
After about 7-10 days incubation, hybridomas
should be appearing as small colonies and culture
supernatants were taken to screen for antibodies. Only
antibody-producing hybridorna colonies were expanded and
cloned by limiting dilution. Cloned cells must be tested
again for antibody production and expanded. Positive
cultures should be recloned again. Finally, several
antibody—producing hybridorna cell lines specixically
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against ADH were obtained
5.3 Troubleshooting in monoclonal antibody production
Many of the difficulties encountered during the
production of monoclonal antibody can be avoided by
carefully planning before fusion is started. It is
particularly important that the screening assay for
detecting antibody is worked out in advance.
5.3.1 Fatality of strongly immunized mice in final booster
When the selected mouse was lastly boostered
with ADH antigens, its body may already have had a high
titer of the corresponding circulating antibodies. if
this is so, the intravenous injection of antigens could
cause immediate localized precipitation of antigen-
antibody complex, which would block the capillaries
resulting in the death of the animal.
Human ADH antigens are highly immunogenic in
different strains of animals due to xenogenic
differences. Therefore, mouse immunized twice with
antigen would show high antibody response and precaution
should be taken to avoid anaphylaxis during
immunization.
5.3.2 Infection
Infection by bacteria, yeast anc1 rungs are
commmonly encountered. When cultures were contaminated,
they were discarded at once and all the stock culture
medium and FBS should be tested for contamination.
Incubators together with laminar flow hood were cleaned
with 70% ethanol or lysol several times. Culture plates
not showing contamination yet should be isolated in a
air-tight box.
5.3.3 Hybrids cease to secrete antibody.
This will occur if non-secreting clones were
allowed to overgrow the hybridomas. Our H02al cell line
was lost in this way. Frequent assay of antibody
secretion is thus needed. Moreover, if a cell line has
been passaged for a long time, it is better to start
with a new frozen stock.
5.3.4 Difficulties in cloning
Some single hybrid cells seemed to grow poorly
during cloning.. To rescue them, we have added
conditioned medium together with 0.05 mM
2-mercaptoethanol and 20% FBS. Feeder cells at a level
of 5 X 10 cellswell may also help, however, too many
of them would cause crowding and do harm.
Recently we have used a chemically defined
medium, 0pti-rnem™I (Gibco Laboratories) containing rich
amount of growth factors and low amount of phenol red
indicator for fusion and cloning. This medium needs
only to be supplemented with 4% FBS in fusion, 2-4% FBS
in cloning, only 0.5-2% FBS in growth of myeloma and
114
established hybridomas. Whether this medium is more
superior than our existing one remains to be determined.
5.4 Discussion on the scheme of purification of antibodies
Up to two-thirds of the antibodies were lost in
the ammonium sulfate precipitation step. It is
suspected that the already diluted ascitic fluid( three
fold} was still too concentrated( 50 mg/ml). The
proteins may interfere with each other and prevent the
complete precipitation of the antibody. To overcome
this, a longer stirring time with sufficient ammonium
sulfate may provide a better yield. Diluting the
ascitic fluid by about five times is another alternative,
but it requires the handling of a larger volume of
solution.
5.5 Discussion on the characterization of the four
monoclonal antibodies to human ADH
Four monoclonal antibodies have so far been
produced. One belongs to the IgGI class( H02b1) and
three to IgM class( HOlal, HOlbi and bFll). These
monoclonal antibodies have been produced in large
quantities from ascites of hybridoma-bearing mice. They
were all purified in a purification scheme designed for
their antibody class. H02b1, an IgG type of antibody
was purified by DEAE-cellulose chromatography, whereas
antibodies HOlal, HOlbl and bFll( all IgM) were
purified with Sephadex G200 spun column.
The purified antibodies were then used to study
their specific binding to ADH. The inhibition of
ensyme activity at a single substrate concentration of
ethanol was found to be dependent on antibody
concentration and length of incubation. This phenomenon
is probably due to the formation of.an antibody-antigen
complex and the subsequent induced conformational change
of the ADH structure. However, detailed study of the
molecular mechanism of this inhibition would require
highly purified and homogeneous antibody.
From the data of the four inhibition curves we
presented in Fig. 4.1, 4.2, 4.3 and 4.4, no 100%
inhibition of ensyme activity was found. Yet at higher
concentrations of the antibodies, visible protein
precipitation was.observed. When this preparation was
assayed, ensyme activity was completely lost. It is
not unreasonable to speculate that the 5 ul of ensyme
containing 2.178 ug protein could be completely
precipitated with the amount of antibodies added
5.6 Scopes of future studies of monoclonal antibodies to ADH
The study of the inhibition of ensyme activity
by the four monoclonal antibodies at different
substrate( ethanol) concentrations would give us
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information on whether the inhibiting is competitiv or
non-competitive. Meanwhile, using other substrates,
such as methanol, isopropanol and cyclohexanol can allow
us to determine whether the inhibition is substrate-
dependent or not. As ADH activity is pH sensitive, so
the study of their catalytic kinetics at various pH may
furnish additional information.
If a antibody is found to bind specifically to
one isoenzyme, it can serve as a ligand in affinity
chromatography to purify that particular class of
isoenzyme. Monoclonal antibody coupled with a
fluoresent label can be used as a marker to identify the
distribution of ADH in different types of tissues by
histochemical techniques.
Another potential area for future study is to
use our monoclonal antibodies to determine their binding
and inhibition characteristics on ADH isolated from
other species. This can help to understand the
evolutionary trend of this enzyme. Among higher plants,
ADH from maize is best characterized (Freeling, 1981).
ADH in maize is found to be one of the stress proteins'
produced during anaerobic treatment( under anaerobic
condition, glucose are oxidized to phosphoenol pyruvate,
later passing many pathways, finally forming
acetaldehyde, which is converted to ethanol by ADH.
Whether ADH or its isoenzyme level in human will respond
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similarly under stress is unknown. The monoclonal
antibodies isolated in this study could certainly be
utilized to carry- out investigation of this nature.
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